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Endometriosis is a chronic gynaecological disease affecting millions of women 
worldwide. It is defined as the presence of endometrial-like tissue outside the 
uterus and, although in some cases it may remain asymptomatic, it is often 
associated with severe pelvic pain and infertility, thus having a major impact 
both on women suffering from it as well as on their families. 
The ‘gold standard’ for the diagnosis of endometriosis is laparoscopic 
visualization of endometriotic lesions. Therefore, due to the lack of an effective 
non-invasive diagnostic technique and the large variability in disease 
symptoms, the right diagnosis is often delayed for years. 
Despite its high prevalence, which is about 10% of women of reproductive 
age, the exact cause of endometriosis is still unknown. Several theories about its 
pathogenesis have been proposed, but to date none of them has been fully 
confirmed, nor do they entirely explain all the mechanisms associated with the 
disease development. In addition, it has been hypothesized that different types 
of endometriotic lesions may have diverse origins. Therefore, it is likely that 
endometriosis is a multifactorial disease caused by the interaction of several 
different factors. 
Since familial aggregation of endometriosis has been observed, genetic 
factors are thought to contribute to disease development. Identifying the genes 
involved in susceptibility to endometriosis could help us understand better 
various disease mechanisms and thus would aid in the development of new 
therapeutic methods. Given that endometriosis is considered to be an oestrogen-
dependent disease, genes involved in sex steroid biosynthesis and signalling are 
good candidates for a genetic association study. For the present thesis we 
selected three genes encoding for oestrogen and progesterone receptors and two 
encoding for the key-enzymes involved in oestrogen production. Additional five 
genes were included in the study based on the most common disease theory, 
Sampson’s implantation hypothesis, which suggests the growth of endo-
metriotic lesions from retrogradely transported endometrial cells and implies the 
importance of tissue remodelling, neoangiogenesis and reduced apoptotic activ-
ity in disease development. 
In addition to genetic factors, impaired function of the immune system and 
elevated levels of certain autoantibodies have been reported in association with 
endometriosis. Identifying disease-specific autoantibodies might be useful for 
the development of minimally-invasive techniques for the diagnosis of 
endometriosis. In view of that, autoantibodies against survivin, a protein which 
belongs to the family of apoptosis inhibitors and is mostly expressed in cancer 




2. REVIEW OF LITERATURE 
2.1. Endometriosis 
Endometriosis is a chronic gynaecological disease defined as the presence of 
endometrial glands and stroma outside the uterine cavity. Endometriotic lesions 
are generally located on the pelvic peritoneum and viscera, as well as in the 
rectovaginal septum and sacrouterine ligaments. In rare cases ectopic endo-
metrium can be found also in the abdominal wall, pleura and in the central 
nervous system. Endometriosis is predominantly found in women of repro-
ductive age and its main symptoms include severe dysmenorrhoea, chronic 
pelvic pain, deep dyspareunia, and infertility. The diagnosis is usually made by 
visual inspection of the pelvis at laparoscopy. Since it is an invasive procedure, 
it is difficult to measure the population prevalence of endometriosis. It is 
estimated that around 10% of women of reproductive age suffer from endo-
metriosis (Giudice and Kao 2004), including 6% of fertile women, and most 
importantly, up to 45–55% of infertile women undergoing laparoscopy have 
endometriosis (Mahmood and Templeton 1991; Calhaz-Jorge et al. 2004; 
Hemmings et al. 2004).  
Endometriosis may present with three distinct forms of lesions: superficial 
endometriotic implants on the pelvic peritoneum and on the ovaries (peritoneal 
endometriosis), ovarian cysts lined by endometrial mucosa (endometriomas), 
and nodules comprised of endometriotic tissue, adipose and fibromuscular 
tissue, residing between the rectum and the vagina (rectovaginal endometriotic 
nodules). All three forms may occur as single or in combination. Whether these 
three types are variants of the same pathologic process or are caused by 
different mechanisms is not clear yet (Nisolle and Donnez 1997; Burney and 
Giudice 2012; Donnez 2012).  
The common features of endometriotic lesions are the presence of endo-
metrial cells, chronic bleeding, and inflammatory reaction which causes 
scarring and the formation of adhesions in the peritoneal cavity. Based on the 
localization, number, size and depth of invasion of ectopic lesions, and the 
presence of adhesions, endometriosis is classified into four different stages:  




Table 1. Classification of endometriosis by points assigned based on the location, size 
and depth of endometriotic lesions, and the presence of adhesions (ASRM 1997). 
 Endometriosis < 1cm 1-3cm > 3cm 
Peritoneum 
Superficial 1 2 4 
Deep 2 4 6 
Ovary 
Right 
Superficial 1 2 4 
Deep 4 16 20 
Left 
Superficial 1 2 4 











Filmy 1 2 4 
Dense 4 8 16 
Left 
Filmy 1 2 4 
Dense 4 8 16 
Tube 
Right 
Filmy 1 2 4 
Dense 4 8 16 
Left 
Filmy 1 2 4 
Dense 4 8 16 
Posterior cul-de-sac obliteration 
Partial Complete 
4 40 
Total score 1-5 6-15 16-40 > 40 
Stage I – minimal II – mild III – moderate IV – severe 
 
 
2.2. Pathogenesis of endometriosis 
Despite its relatively high prevalence, the aetiology and pathogenesis of 
endometriosis are not fully understood. Coelomic metaplasia and embryonic 
rest theories suggest that endometriotic lesions develop from mesothelial cells 
or from cells of mullerian origin, respectively, which due to a yet undetermined 
stimulus differentiate into endometrium-like tissue (Sasson and Taylor 2008; 
Burney and Giudice 2012). These mechanisms could explain the presence of 
ectopic endometrium in the rectovaginal septum and the rare occurrence of 
endometriosis before or in early puberty. However, the most common theory, 
thus far, is Sampson’s implantation theory (Sampson 1927b), according to 
which during menstruation endometrial cells reflux through the fallopian tubes 
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into the abdominal cavity where they implant on extrauterine structures and 
subsequently form ectopic endometriotic lesions. Sampson also suggested that 
endometrial cells might spread through veins and lymphatic vessels, thus giving 
rise to distant ectopic lesions outside the pelvis, for example in the lungs and 
brain (Sampson 1927a). Implantation theory is supported by the facts that viable 
endometrial cells can be found in menstrual and peritoneal fluid (Koninckx et 
al. 1980), and that endometriosis often develops in women with vaginal 
obstruction of outflow (Olive and Henderson 1987). 
In line with Sampson’s hypothesis, recent data suggest a potential role for 
the endometrial stem/progenitor cells in the pathogenesis of endometriosis. 
Stem cells are speculated to function in the cyclic regeneration of the endo-
metrium and endometriotic implants are thought to result from the retrograde 
menstruation of these cells (Sasson and Taylor 2008). 
Up to 90% of women with patent fallopian tubes exhibit some grade of retro-
grade menstruation (Halme et al. 1984), but only a minority of them develops 
endometriosis, considering that its prevalence is around 10%. Therefore, it is 
likely that also other factors are involved in the development of this disease. 
One possible explanation could be alterations in the eutopic endometrium, as 
differences in gene expression profiles in endometrium of women with and 
without endometriosis have been demonstrated (Kao et al. 2003; Burney et al. 
2007). Also impaired function of the immune system has been implicated in the 
development of endometriosis (Dmowski 1995; Kyama et al. 2003; Herington 
et al. 2011). Increased levels of activated macrophages, cytokines, T and B cells 
are found in the peritoneal fluid of endometriosis patients, indicating a local 
inflammatory reaction which may promote the establishment of endometriotic 
lesions. In addition, although the ability of immune cells to produce cytokines 
and growth factors is retained, altered function of regulatory T cells and a de-
crease in natural killer (NK) cell and T cell cytotoxic activity and in macro-
phage phagocytic capacity has been observed, which further contributes to the 
survival of sloughed endometrial cells and to the formation of ectopic implants 
(Kyama et al. 2003; Herington et al. 2011). 
 
 
2.3. Endometriosis and infertility 
As mentioned above, endometriosis is often associated with reduced fertility. In 
normal couples, fecundity, defined as the probability of a woman achieving a 
live birth in a given month, ranges from 0.15 to 0.20. In untreated women with 
endometriosis monthly fecundity tends to be lower, being in the range of 0.02 to 
0.10 (Ozkan et al. 2008; Bulletti et al. 2010). In addition, while the general 
prevalence of endometriosis is around 10%, it is diagnosed in about 50% of 
infertile women undergoing laparoscopy (Calhaz-Jorge et al. 2004; Hemmings 
et al. 2004). Despite intensive research, however, the precise mechanisms 
causing infertility in endometriosis patients are still unclear (Bulletti et al. 2010; 
ASRM 2012; Carvalho et al. 2012). 
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In case of moderate-severe endometriosis (stage III–IV), infertility is likely 
related to the presence of adhesions in the peritoneal cavity, which may cause 
anatomical distortion of pelvic organs and can thus hinder oocyte release from 
the ovary, ovum capture and transport (Ozkan et al. 2008; Carvalho et al. 2012). 
However, as women with stage I–II disease, with little anatomical effect, also 
suffer from infertility, additional mechanisms affecting reproductive function 
must be involved. 
Studies on women undergoing assisted reproductive technologies (ART) 
have shown correlations between endometriosis and a decrease in different 
outcomes, like oocyte retrieval rate, fertilization rate, implantation rate and 
pregnancy rate (Barnhart et al. 2002). Others, however, have reported only a 
reduction in the number of oocytes retrieved (Suzuki et al. 2005). These 
observations suggest that different stages of the reproductive process may be 
impaired in women suffering from endometriosis. Mechanisms that reduce 
fertility may include endocrine and ovulatory disorders, impaired folliculo-
genesis and altered immunological environment in the peritoneal cavity, which 
may have adverse effects on the function of the oocyte, sperm, embryo and 
fallopian tubes. In addition, immunological and hormonal abnormalities in the 
eutopic endometrium may be involved, causing reduced endometrial receptivity 
and defective implantation. Impaired fertility may also be related to poor oocyte 
and embryo quality, as women with moderate to severe endometriosis who 
receive oocytes from disease-free women appear to have normal endometrial 
receptivity and pregnancy rates (ASRM 2012). 
Although a firmly established causal relationship between endometriosis and 
infertility is still lacking, it has been shown that treatment of endometriosis may 
improve fertility in these women (Ozkan et al. 2008). 
 
 
2.4. Endometriosis and genetics 
There is evidence to suggest that susceptibility to endometriosis may be 
influenced by genetic factors. Familial clustering of endometriosis has been 
described in humans and in rhesus monkeys (Kennedy 1999). A study by 
Simpson and colleagues showed that the incidence of endometriosis in the first-
degree relatives of affected women was about seven times higher than among 
women without such a family history (6.9% vs. 1.0%) (Simpson et al. 1980). 
Similar findings have been reported also in other studies (Coxhead and Thomas 
1993; Moen and Magnus 1993). Additionally, severe forms of endometriosis 
were observed markedly more often in familial than in sporadic cases (61% vs. 
23%) (Bischoff and Simpson 2004). Evidence for genetic contributions to 
endometriosis risk also comes from twin studies, which show a high rate of 
concordance for endometriosis among monozygotic twin sisters (Moen 1994; 
Hadfield et al. 1997; Treloar et al. 1999). 
These data suggest that endometriosis is a polygenic/multifactorial disease, 
meaning that many different genes contribute to disease risk and that the 
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contribution of each gene individually is small. Identifying which genetic fac-
tors influence susceptibility to endometriosis could help us understand better the 
pathogenetic mechanisms of this disease and to develop new methods for diag-
nosis and treatment of endometriosis. 
Numerous studies on single candidate genes have been carried out in diffe-
rent populations, however, often the results have been inconsistent (Mont-
gomery et al. 2008; Dun et al. 2010; Rahmioglu et al. 2012). Genome-wide 
linkage and genome-wide association studies (GWAS) have identified loci on 
chromosome 1, 2, 6, 7, 9, 10 and 12 to be associated with endometriosis 
(Treloar et al. 2005b; Zondervan et al. 2007; Uno et al. 2010; Painter et al. 
2011a; Nyholt et al. 2012; Albertsen et al. 2013). Some of the genes within or 
close to these loci, like CDKN2BAS (cyclin-dependent kinase inhibitor 2B 
antisense RNA), WNT4 (wingless-type mouse mammary tumour virus 
integration site family, member 4), HOXA10 (homeobox A10), HOXA11 
(homeobox A11) and CYP2C19 (cytochrome P450, family 2, subfamily C, 
polypeptide 19) are considered plausible candidate genes (Uno et al. 2010; 
Painter et al. 2011a; Painter et al. 2011b; Pagliardini et al. 2013), yet they 
explain only a small part of the variance in susceptibility to endometriosis, 
suggesting the additional involvement of other genetic variants. 
 
 
2.5. Endometriosis and sex steroids 
Endometriosis is considered to be an oestrogen-dependent disease, as it occurs 
mostly in women of reproductive age; symptoms usually appear after menarche 
and regress spontaneously after menopause (Kitawaki et al. 2002; Bulun 2009). 
In addition, pharmacological suppression of oestrogen by gonadotropin- 
releasing hormone (GnRH) analogues, oral contraceptives, progestins or aroma-
tase inhibitors provides the regression of endometriotic lesions and reduces 
pain, while discontinuation of this therapy or introducing oestrogen replacement 
therapy in postmenopausal women may both give a relapse of the disease. 
The growth of endometrial tissue is regulated by oestrogen and progesterone, 
with oestrogen stimulating proliferation and progesterone opposing the effects 
of oestrogen and inhibiting cell proliferation (Graham and Clarke 1997). In 
normal conditions, oestrogen is mainly produced in the ovaries, but in smaller 
quantities also in adipose tissue and skin, where circulating androstenedione is 
converted by different steroidogenic enzymes into oestrone and subsequently to 
the biologically more active form, oestradiol. In women with endometriosis, 
however, oestrogen is produced also directly in the endometriotic tissue, since 
differently from the eutopic endometrium, it expresses all the necessary 
enzymes for oestrogen biosynthesis, including the two key enzymes cytochrome 
P450 aromatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) 
(Noble et al. 1996; Smuc et al. 2007) (Figure 1). Thus the local level of 





Figure 1. The role of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) and 
aromatase in the production of oestradiol, and the function of oestrogen and 
progesterone in endometriotic lesions mediated through oestrogen receptors α (ERα) 
and β (ERβ), and through progesterone receptors A (PR-A) and B (PR-B). 
 
 
The role of progesterone in the eutopic endometrium is to exert an anti-
oestrogenic effect, inhibiting tissue proliferation (Graham and Clarke 1997). In 
case of endometriosis, however, endometriotic tissue fails to respond adequately 
to progesterone, which additionally contributes to the stimulating effect of the 
abnormally high oestrogen levels (Bulun et al. 2006). 
Besides their direct effect on endometrial proliferation, oestrogen and 
progesterone are also involved in the regulation of the immunological micro-
environment at eutopic and ectopic sites (Herington et al. 2011). Therefore, an 
imbalance in their function may influence the growth of endometriotic lesions 
also indirectly. 
Considering the heavy involvement of oestrogen and progesterone in the 
development of endometriosis, a search for candidate genes should include 
those involved in biosynthesis and signalling pathways of sex steroids. 
 
 
2.5.1. Oestrogen receptors 
In humans, the effects of oestrogens are classically mediated via two oestrogen 
receptors ERα and ERβ, which are members of the nuclear receptor subfamily 3 
and function as ligand-activated transcription factors. They share a common 
structural and functional organization, with distinct domains for ligand binding, 
DNA binding, and transcriptional activation (Enmark and Gustafsson 1999). 
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ERs modify the expression of many different genes involved in cell growth, 
proliferation and differentiation by binding to oestrogen response elements 
(ERE) located in gene promoters. Both receptors can form homodimers or 
heterodimers with the other subtype (Enmark and Gustafsson 1999). ERα and 
ERβ are encoded by two different genes, ESR1 (6q25.1) and ESR2 (14q23.2), 
respectively (Walter et al. 1985; Mosselman et al. 1996). Both genes are subject 
to alternative splicing and, besides the wild-type receptor, at least two other 
ERα isoforms and four ERβ isoforms exist (Gibson and Saunders 2012). 
However, the impact of these ER variants on cell function remains poorly 
understood thus far. ERα and ERβ show partially overlapping but also unique 
functions and expression patterns in human tissues (Matthews and Gustafsson 
2003). In the reproductive tract ERα is primarily expressed in the uterus, 
whereas ERβ is more expressed in the ovary (Matthews and Gustafsson 2003). 
In tissues co-expressing ERα and ERβ, cellular response to estrogens depends 
on the ERα/ERβ ratio, since ERβ tends to inhibit ERα-mediated gene 
expression (Hall and McDonnell 1999) (Figure 1). Both oestrogen receptors are 
expressed in normal endometrium as well as in endometriotic lesions 
(Moutsatsou and Sekeris 2003), and genetic variants in their respective genes 
could alter relative expression levels of receptor subtypes, thus modifying tissue 
sensitivity to oestrogens. 
Within the ESR1 gene locus, more than 2800 single nucleotide poly-
morphisms (SNP) have been identified thus far (snpper.chip.org). One of the 
most frequently studied polymorphisms is the c.454 -397T/C SNP in intron 1 
(rs2234693), defined by the restriction enzyme PvuII. The PvuII C allele creates 
a possible binding site for the myb family of transcription factors and might in 
certain conditions amplify ESR1 transcription and oestrogen actions (Herrington 
et al. 2002). Another potentially functional polymorphism is a (TA)n microsatel-
lite repeat situated upstream from the coding region. ESR1 gene has at least 
seven different promoters, which produce different mRNA molecules with 
unique 5’-UTRs, but mostly with identical coding regions (Kos et al. 2001). The 
(TA)n locus lies between exons B and C (nomenclature by Kos et al, 2001) and 
therefore might influence alternative promoter usage and the expression of ERα 
(Becherini et al. 2000). Both, the PvuII T/C SNP and the (TA)n repeat, have 
been found to be associated with oestrogen-dependent diseases like breast can-
cer (Anghel et al. 2006; Li et al. 2010) and osteoporosis (Gennari et al. 2005). 
Several studies have also investigated their role in endometriosis, but with 
conflicting results (Georgiou et al. 1999; Kitawaki et al. 2001; Wang et al. 
2004; Hsieh et al. 2005b; Kim et al. 2005b; Luisi et al. 2006; Renner et al. 
2006; Hsieh et al. 2007b; Xie et al. 2008; Govindan et al. 2009). 
The ESR2 gene contains over 700 SNPs (snpper.chip.org). In addition, there 
is a highly polymorphic dinucleotide (CA)n repeat polymorphism in intron 5, 
which similarly to the ESR1 gene variants, has been associated with breast 
cancer risk (Anghel et al. 2006; Tsezou et al. 2008) and bone mineral density 
(Gennari et al. 2005). However, according to our knowledge, there are no 
published studies investigating its role in endometriosis. 
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2.5.2. Progesterone receptor 
The physiologic effects of progesterone are mediated via progesterone receptor 
(PR) which, like ERs, belongs to the steroid receptor superfamily and functions 
as a ligand-activated transcription factor. PR is expressed as two isoforms, PR-
A and PR-B, which after ligand binding form homo- or heterodimers and 
regulate the expression of target genes by binding to the progesterone-response 
elements (PRE) in their promoter regions (Graham and Clarke 1997). Both 
isoforms are encoded by a single gene, PGR (11q22-q23), using separate 
promoters and translational start sites. PR-B contains an additional 165 amino 
acids at the N terminus and acts mostly as a transcriptional activator, while  
PR-A represses the transcriptional activity of PR-B and of other steroid 
receptors (Conneely et al. 2003) (Figure 1). As the two isoforms are functio-
nally different, tissue responsiveness to progesterone may be modulated by 
alterations in the ratio of PR-A and PR-B (Graham and Clarke 1997). Both PR 
isoforms are expressed in normal endometrium as well as in endometriotic 
lesions (Mote et al, 1999; Misao et al, 1999). Therefore, genetic variants in the 
PGR capable of altering the expression levels of receptor subtypes might 
modify tissue sensitivity to progesterone and influence susceptibility to 
endometriosis. 
In the PGR gene, over 900 SNPs have been described so far 
(snpper.chip.org). Two widely studied functional variants are a +331G/A SNP 
(rs10895068) in the PGR promoter region and the PROGINS haplotype, which 
consists of a single amino acid substitution in exon 4 (Val660Leu), a silent 
point mutation in exon 5 (His770His), and a 306-bp Alu-insertion (Ins) in  
intron 7 which are in complete LD with each other (De Vivo et al. 2002). The 
+331G/A SNP A allele creates a unique transcription start site that favours the 
production of PR-B isoform (De Vivo et al. 2002), while PROGINS 
(660Leu/770His/AluIns) has been shown to reduce PR-A mediated inhibition of 
cell proliferation (Romano et al. 2007). Both of these polymorphisms have been 
associated with the risk of different gynaecological tumours (De Vivo et al. 
2002; De Vivo et al. 2003; Govindan et al. 2007; Pearce et al. 2008). Several 
studies have investigated their role also in endometriosis, but the results have 
been conflicting (Wieser et al. 2002; Lattuada et al. 2004; Treloar et al. 2005a; 
De Carvalho et al. 2007; Govindan et al. 2007; van Kaam et al. 2007; Gentilini 




One of the key enzymes in oestrogen biosynthesis is cytochrome P450 
aromatase, which catalyses the conversion of testosterone and androstenedione 
to oestradiol and oestrone, respectively (Figure). It is expressed in a number of 
human tissues, like gonads, placenta, adipose tissue, skin, brain etc (Bulun et al. 
1997). Normal eutopic endometrium does not express aromatase, but in eutopic 
and ectopic endometrium of women with endometriosis, it is significantly up-
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regulated (Noble et al. 1996; Smuc et al. 2007), suggesting the existence of 
local oestrogen production and the importance of aromatase in the pathogenesis 
of endometriosis. 
Aromatase is encoded by the CYP19A1 (cytochrome P450, family 19, 
subfamily A, polypeptide 1) gene (15q21.1), which consists of 9 coding exons 
(II-X) and is expressed in a tissue-specific manner by using different promoters 
(Sebastian 2001). In endometriotic tissue aromatase expression is regulated 
mostly by the gonad-specific promoter II (Bulun et al. 2005). Although the 
transcripts of aromatase have different 5’-UTRs they are spliced onto a common 
junction 38 bp upstream of the translation start site, meaning that the sequence 
encoding the open reading frame and consequently the expressed protein are 
identical in each case (Bulun et al. 2005). 
The CYP19A1 gene contains more than 1000 SNPs (snpper.chip.org). Three 
commonly studied polymorphisms in the CYP19A1 gene include a tetra-
nucleotide (TTTA)n repeat and a 3-bp (TCT) insertion/deletion (Ins/Del) 
polymorphism in intron 4, and a C/T SNP (rs10046) in the 3’-UTR of exon 10. 
These polymorphisms have been shown to correlate with aromatase activity and 
to influence susceptibility to oestrogen-dependent diseases (Kristensen et al. 
2000; Gennari et al. 2004). Studies on their involvement in endometriosis, 
however, have yielded inconsistent results (Kado et al. 2002; Arvanitis et al. 
2003; Huber et al. 2005; Hur et al. 2007; Vietri et al. 2009). 
 
 
2.5.4. 17β-hydroxysteroid dehydrogenase type 1 
A second key enzyme in oestrogen biosynthesis is 17β-hydroxysteroid 
dehydrogenase type 1 (17β-HSD1) which converts oestrone to the biologically 
more active oestradiol (Figure). It is a cytosolic protein and functions as a 
homodimer (Labrie et al. 2000). 17β-HSD1 is abundantly expressed in different 
tissues, like ovaries, breasts and placenta (Peltoketo et al. 1999). Normal 
endometrium, however, contains only low levels of 17β-HSD1, but in eutopic 
and ectopic endometrium of women with endometriosis its expression is 
significantly up-regulated (Smuc et al. 2007), suggesting a potential role in 
disease development.  
17β-HSD1 is encoded by the HSD17B1 gene (17q11-q21) which contains 
about 130 SNPs (snpper.chip.org), including a +1954A/G SNP (Ser312Gly) in 
exon 6 (rs605059). The amino acid change related to this SNP does not appear 
to influence the catalytic or immunological properties of the 17β-HSD1 enzyme 
(Puranen et al. 1994), yet it has been shown to be associated with circulating 
oestradiol levels (Setiawan et al. 2004). Thus far only one study has 
investigated its role in endometriosis and reported a significant association with 





2.6. Tissue remodelling and angiogenesis in endometriosis 
According to Sampson’s implantation theory, endometrial cells reflux to the 
abdominal cavity and implant on the peritoneum thus giving rise to the 
development of endometriotic lesions. This requires the involvement of 
different physiologic processes like cell adhesion and proliferation, tissue 
remodelling and neoangiogenesis to allow the ectopic growth of endometrial 
implants. Remodelling of the connective tissue requires both breakdown and 
resynthesis of extracellular matrix (ECM) components. Different enzymes can 
be involved in the degradation of ECM proteins, but the primary contributors 
are believed to be matrix metalloproteinases (MMPs) (Hulboy et al. 1997). 
MMPs are a group of structurally-related extracellular and membrane bound 
proteinases that degrade ECM and basement membrane components throughout 
the body (Hulboy et al. 1997). Their activity influences several different 
biological processes such as embryonic development, organ morphogenesis, 
angiogenesis, wound healing etc (Birkedal-Hansen et al. 1993). MMPs also 
participate in the control of reproductive function by regulating the structural 
changes that occur in the ovaries and uterus throughout the menstrual cycle 
(Hulboy et al. 1997; Curry and Osteen 2001). The activity of MMPs is 
controlled by steroid hormones, cytokines, growth factors, and tissue and 
plasma inhibitors of metalloproteinases (Hulboy et al. 1997; Nelson et al. 2000). 
In endometrium, the expression of MMPs depends on the phase of the 
menstrual cycle: during menstruation, when tissue breakdown occurs they are 
highly expressed, but throughout the rest of the cycle their concentrations are 
low or undetectable in general (Hulboy et al. 1997). Thus, precisely controlled 
regulation of MMP expression is essential for normal tissue remodelling during 
menstrual cycle. An increase in baseline MMP levels could enhance the 
proteolytic activity and invasive properties of endometrial cells and might 
therefore favour their peritoneal implantation and the development of 
endometriotic lesions. 
Once endometrial cells have implanted on the peritoneum the establishment 
of a new blood supply is a crucial event for their survival and the subsequent 
development of ectopic lesions. It has been demonstrated that tumour implants 
are not able to grow beyond a volume of 3 mm3 unless they develop a new 
blood supply (Folkman 1995). It can be assumed that the same mechanism 
applies for the growth of endometriotic lesions. Therefore, active neo-
angiogenesis and vascular remodelling are thought to be important mechanisms 
in the pathogenesis of endometriosis. In fact, peritoneal fluid from women with 
endometriosis, as well as their eutopic and ectopic endometrial tissue, have been 
shown to have more angiogenic activity compared to normal controls (Taylor et 





2.6.1. Matrix metalloproteinases 2 and 9 
Endometrial stromal cells express several MMPs, including MMP-2 (gelatinase 
A) and MMP-9 (gelatinase B), which seem to have an important role in 
endometrial ECM breakdown (Curry and Osteen 2001). These proteinases may 
play an active part in the establishment and progression of endometriosis, since 
altered MMP-2 and MMP-9 expression profiles have been reported in eutopic 
and ectopic endometrial tissues obtained from women with endometriosis 
(Chung et al. 2001; Shaco-Levy et al. 2008; Di Carlo et al. 2009) (Figure 2). In 
particular MMP-2 seems to correlate with endometriosis aggressiveness, as its 
expression in invasive colorectal endometriosis was found to be significantly 
higher than in superficial peritoneal lesions (Weigel et al. 2012). Also 
circulating MMP-2 levels are reported to be higher in women with stage III-IV 
disease than in those with stage I–II endometriosis (Malvezzi et al. 2012). In 
addition, down-regulation of both MMP-2 and MMP-9 activities by curcumin 
has been shown to inhibit endometriosis development in mouse models 
(Swarnakar and Paul 2009; Jana et al. 2012), suggesting their importance in the 
establishment and growth of endometriotic implants. 
MMP-2 and MMP-9 are encoded by the MMP2 (16q13-q21) and MMP9 
(20q11.2-q13.1) genes, which contain about 450 and 250 SNPs, respectively 
(snpper.chip.org). Some of the SNPs in the promoter regions of MMP2 and 
MMP9 have been shown to lead to changes in gene expression levels and thus 
could be associated with a predisposition to a variety of diseases (Zhang et al. 
1999; Yu et al. 2004; Zhou et al. 2005; Kang et al. 2008a). In MMP2, four 
highly linked promoter SNPs: -1575G/A (rs243866), -1306C/T (rs243865),  
-790T/G (rs243864) and -735C/T (rs2285053) have been described. The minor 
alleles of the -735C/T and -1306C/T SNPs are associated with diminished 
promoter activity due to the disruption of a transcription factor Sp1 binding 
element (Price et al. 2001; Yu et al. 2004). Also in the MMP9 gene, the  
-1562T/C SNP (rs3918242) has been reported to influence its transcriptional 
activity (Zhang et al. 1999). A few genetic association studies have been carried 
out to find relations between these polymorphisms and endometriosis, but so far 
mostly on women of Asian origin, with majority reporting negative results 







Figure 2. The possible role of matrix metalloproteinases (MMP) 2 and 9, vascular 
endothelial growth factor (VEGF) and angiotensin I-converting enzyme (ACE) in the 
development of endometriosis; ECM – extracellular matrix. 
 
 
2.6.2. Vascular endothelial growth factor 
Endometrial angiogenesis is controlled by sex steroids which exert their effect 
indirectly via numerous growth factors. One of the most important factors is 
vascular endothelial growth factor (VEGF), a heparin-binding homodimeric 
glycoprotein, which increases vascular permeability and induces endothelial cell 
proliferation, migration, differentiation, and capillary formation (Ferrara 2004). 
Different studies have shown altered VEGF mRNA expression and elevated 
protein levels in eutopic and ectopic endometrium as well as in the peritoneal 
fluid of women with endometriosis (Taylor et al. 1997; Donnez et al. 1998; 
Bourlev et al. 2006; Di Carlo et al. 2009). It has been suggested that after the 
attachment of endometrial cells, high VEGF levels could stimulate the 
formation of the subperitoneal vascular network and thus facilitate implantation 
and viability of endometrial cells (Donnez et al. 1998) (Figure 2). 
VEGF is encoded by the VEGFA gene (6p12), which consists of eight exons 
and through alternative splicing produces different transcript variants, encoding 
either freely secreted or cell surface-bound VEGF isoforms (Ferrara 2004). The 
VEGFA gene contains over 200 SNPs (snpper.chip.org). Some of these variants, 
like -2578A/C (rs699947), -1154G/A (rs1570360), -634G/C (also known as 
+405G/C; rs2010963), and +936C/T (rs3025039) SNPs have been associated 
with altered expression of VEGF (Koukourakis et al. 2004; Szeto et al. 2004; 
Steffensen et al. 2010). Several studies have been carried out to investigate the 
role of these VEGFA polymorphisms in susceptibility to endometriosis, but the 
results have been inconsistent (Bhanoori et al. 2005; Kim et al. 2005a; Ikuhashi 
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et al. 2007; Gentilini et al. 2008a; Kim et al. 2008; Zhao et al. 2008; Cosin et al. 
2009; Liu et al. 2009; Altinkaya et al. 2011). 
 
 
2.6.3. Angiotensin I-converting enzyme 
Angiotensin I-converting enzyme (ACE) is a major component of the renin–
angiotensin system which catalyzes the conversion of angiotensin I to the potent 
vasoconstrictor angiotensin II. Angiotensin II regulates blood pressure and 
fluid-electrolyte homeostasis, but besides its systemic effects it also modulates 
the angiogenic reaction and could be involved in both normal and pathological 
angiogenesis (Chua et al. 1998; Pupilli et al. 1999; Tamarat et al. 2002). It has 
been shown to stimulate cell growth and invasion, and to increase VEGF 
expression in endothelial cells via the angiotensin II type 1 receptor  (Fujiyama 
et al. 2001; Tamarat et al. 2002). In human endometrium, the presence of a local 
renin-angiotensin system has been demonstrated (Li and Ahmed 1996). Since 
angiotensin II has been found to be strongly expressed around endometrial 
blood vessels in the late secretory phase and in the stroma and glandular 
epithelium during the proliferative phase, it is thought to be important in the 
initiation of menstruation and in angiogenesis during endometrial regeneration 
(Li and Ahmed 1996). As angiotensin II production depends on ACE activity, 
an imbalance in ACE expression could affect menstruation and might thus 
predispose certain women to endometriosis (Figure 2). 
ACE is encoded by the ACE gene (17q23.3), which through alternative 
splicing may give rise to different isoforms. Around 300 SNPs have been 
identified in the ACE locus (snpper.chip.org), but the most studied poly-
morphism is a 287-bp Alu insertion/deletion (Ins/Del) polymorphism in intron 
16 (rs4340). It correlates with circulating ACE level, however, its effect on 
blood pressure and cardiovascular diseases seems to be limited (Jeunemaitre 
2008). A few studies have reported also other ACE polymorphisms in asso-
ciation with ACE expression. Two SNPs, -240A/T in the promoter region 
(rs4291) and +2350A/G in exon 17 (Thr776Thr; rs4343) were found to explain 
more than 20% of the total variance in serum ACE level and to be significantly 
associated with blood pressure (Zhu et al. 2001). The impact of ACE variants 
has been widely studied for example in Alzheimer’s disease and in cardio-
vascular diseases (Sayed-Tabatabaei et al. 2006). So far, however, only a few 
studies have investigated their role in endometriosis, reporting conflicting 
results (Hsieh et al. 2005a; Hsieh et al. 2007a; Kowalczynska et al. 2011). 
 
 
2.7. Apoptosis in endometriosis 
Apoptosis is a process of programmed cell death that occurs in multicellular 
organisms and keeps balance between tissue proliferation and degradation. It 
can be initiated by different extra- and intracellular signals and defects in its 
activity are involved in the development of a variety of diseases, for example in 
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tumours. Similarly to neoplastic processes, diminished apoptosis appears to 
have a role in the pathogenesis of endometriosis. According to Sampson’s 
theory, ectopic lesions develop from uterine endometrial cells that disseminate 
into peritoneal cavity during menstruation (Sampson 1927b). As retrograde 
menstrual flow appears to be a physiological phenomenon observed in majority 
of women (Halme et al. 1984), some other mechanisms favouring the survival 
of misplaced endometrial cells must be involved in endometriosis development. 
It has been shown that apoptotic activity in the eutopic endometrium of women 
with endometriosis lacks the normal cyclic variability and is reduced in 
comparison to the endometrium of disease-free women (Dmowski et al. 2001; 
Szymanowski 2007). Furthermore, in endometriotic lesions apoptosis is even 
lower than in the corresponding eutopic endometrium (Dmowski et al. 1998). 
This indicates that increased viability of endometrial cells may be involved in 
their ectopic survival, thus facilitating their implantation and the development 




Survivin is a protein that belongs to the family of inhibitors of apoptosis and its 
expression is regulated in a cell cycle-dependent manner. Initially, survivin 
expression was described in fetal tissues and placenta, and only in a few 
terminally differentiated tissues (Ambrosini et al. 1997), while elevated survivin 
levels were observed in different types of tumours, in association with reduced 
apoptotic activity (Altieri 2003). Later, however, several normal adult tissues 
and cell types were found to express survivin, although at remarkably lower 
levels than in cancer cells (Fukuda and Pelus 2006). The presence of survivin 
mRNA and protein has also been demonstrated in normal cycling endometrium 
(Konno et al. 2000), with its highest levels mostly reported in the proliferative 
phase of the cycle (Lehner et al. 2002; Nabilsi et al. 2010). Survivin expression 
in human endometrium appears to be regulated by sex hormones, as it increases 
after treatment with oestrogen and decreases with the use of progestins (Nabilsi 
et al. 2010). 
Similarly to endometrial cancer, elevated survivin level is characteristic to 
non-malignant endometrial pathologies like endometrial hyperplasia (Erkanli et 
al. 2006) and endometriosis (Ueda et al. 2002). It has been shown that survivin 
expression is significantly higher in peritoneal and ovarian endometriotic 
lesions than in the eutopic endometrium of women with or without 
endometriosis (Ueda et al. 2002; Fujino et al. 2006). Early stage peritoneal 
lesions with high proliferative activity show higher levels of survivin in 
comparison to more advanced lesions, suggesting that in the first stages of 
lesion development survivin may be linked to the escape of endometrial tissue 
fragments from apoptosis (Ueda et al. 2002; Fujino et al. 2006). 
Survivin is encoded by the BIRC5 gene (17q25), which contains about 250 
SNPs (snpper.chip.org). Three polymorphisms in the promoter region, -241C/T 
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(rs17878467), -235G/A (rs17887126) and -31G/C (rs9904341) could be 
associated with gene expression activity. The highly frequent -31G/C SNP is 
located at a CDE/CHR (cell cycle-dependent element/cell cycle homology 
region) repressor element (Xu et al. 2004) and the presence of the C allele has 
been shown to increase survivin transcription level (Jang et al. 2008; Wagner et 
al. 2008; Kawata et al. 2011). The data about low-frequency -235G/A and  
-241C/T SNP effects are more controversial revealing either no impact or 
slightly positive influence of minor alleles on promoter activity (Xu et al. 2004; 
Wagner et al. 2008; Boidot et al. 2010). The role of survivin promoter SNPs has 
been investigated in different neoplastic diseases (Han et al. 2009a; Jaiswal et 
al. 2011; Srivastava et al. 2012), but to our knowledge, there are no studies 
published on endometriosis thus far. 
 
 
2.7.2. Anti-survivin autoantibodies 
Over-expression of survivin in neoplastic tissues has been shown to stimulate 
humoral immunoreactivity as anti-survivin autoantibodies have been found in 
the sera of patients with various forms of cancer (Rohayem et al. 2000; Eto et 
al. 2007; Söling et al. 2007). The percentage of antibody-positive patients may 
vary in different tumour types (Megliorino et al. 2005). In a study on head and 
neck cancer patients anti-survivin autoantibodies were detected in more than 
70% of cases and a positive correlation between antibody titers and disease 
stage was found (Eto et al. 2007). In addition, after cancer treatment a 
significant decrease in antibody levels was observed (Eto et al. 2007). In non-
small cell lung cancer cases, instead, less than 8% of patients had anti-survivin 
antibodies and no correlation with tumour stage or treatment was found 
(Karanikas et al. 2009). 
Women with endometriosis show activation of the humoral immune system, 
as has been evidenced by several studies reporting the presence of anti-
endometrial, anti-ovarian and of other non-specific autoantibodies (lupus 
anticoagulant, anticardiolipin, antinuclear, anti-smooth muscle etc) in patients’ 
sera (Vinatier et al. 1996; Reimand et al. 2001; Randall et al. 2007; Sarapik et 
al. 2010). In one early paper, 40-60% of women with endometriosis were 
reported to have elevated autoantibody titers when tested against a panel of non-
specific autoantigens (Gleicher et al. 1987), while in a more recent study, using 
indirect immunofluorescence detection of anti-endometrial antibodies, about 
80% of endometriosis patients had positive results (Randall et al. 2007). It is not 
clear whether these antibodies reflect a natural response to chronic tissue 
destruction or show a pathologic response leading to a more generalized 
autoimmune dysfunction (Eisenberg et al. 2012), but their presence seems to 
have a negative impact on the reproductive function of endometriosis patients 
(Eisenberg et al. 2012; Haller-Kikkatalo et al. 2012). 
Taking into account the elevated humoral immunoreactivity in women with 
endometrios and the increased expression of survivin in endometriotic lesions, it 
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can be hypothesized that anti-survivin autoantibodies could be present in sera of 
endometriosis patients, and if it were so, their detection might be useful for 
minimally invasive disease diagnosis. To our knowledge, however, no data is 
available about anti-survivin antibodies in endometriosis patients so far. 
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3. AIMS OF THE STUDY 
The general aim of the present study was to evaluate possible associations 
between different candidate genes and susceptibility to endometriosis. In 
addition, we wanted to evaluate if there is any immune reaction to survivin in 
women with endometriosis and whether anti-survivin autoantibody level in 
patients’ sera could be used as a minimally invasive diagnostic disease marker. 
 
Accordingly, the specific aims were the following: 
 
1. To investigate associations between endometriosis and genetic variations 
in different genes involved in sex steroid biosynthesis and signalling: 
ESR1, ESR2, PGR, HSD17B1, CYP19A1. 
 
2. To study the role of polymorphisms in matrix metalloproteinase genes 
MMP2 and MMP9 in susceptibility to endometriosis. 
 
3. To evaluate associations between endometriosis and genetic variants in 
genes involved in angiogenesis: VEGF and ACE. 
 
4. To study the effect of polymorphisms in the apoptosis inhibitor protein 
survivin gene BIRC5 on the risk of endometriosis. 
 
5. To compare the autoimmune reaction to survivin in women with and 




4. MATERIALS AND METHODS 
The study was approved by The Ethics Review Committee on Human Research 
of the University of Tartu, decision nr 138/9. An informed consent was obtained 
from each study participant. 
 
 
4.1.  Study subjects 
A total of 197 women (18–45 years of age) hospitalised for suspected endo-
metriosis or for infertility work-up/treatment were recruited into the study from 
Tartu University Hospital’s Women’s Clinic and Nova Vita Clinic between 
February 2005 and February 2008. Of these patients, 150 had surgically and 
histologically confirmed endometriosis and were used in the study as ‘endo-
metriosis group’ (mean age ± SD: 32.1 ± 6.1 years). Disease stages according to 
the American Society for Reproductive Medicine revised classification system 
(ASRM 1997) were as follows: stage I (minimal) – 53 patients, stage II (mild) – 
39 patients, stage III (moderate) – 36 patients, and stage IV (severe) – 22 
patients.  
Two different control groups were used. For the genetic association studies, 
199 women (30–50 years of age; mean age ± SD: 39.8 ± 5.3 years) with proven 
fertility (at least two children) and no medical history of endometriosis were 
enrolled as ‘population controls’ (control group A). Their DNA samples and 
medical data were obtained from the Estonian Genome Centre, University of 
Tartu. 
For the study on anti-survivin antibodies, 47 women (mean age ± SD: 30.0 ± 
6.1 years) recruited from Tartu University Hospital’s Women’s Clinic who had 
undergone laparoscopy and were found not to have endometriosis were used as 
‘gynaecological controls’ (control group B). 
Peripheral blood samples, taken before the operation, and a clinical data 
questionnaire were collected for each study participant recruited from Tartu 
University Hospital’s Women’s Clinic and Nova Vita Clinic. 
 
 
4.2.  Genotyping of polymorphisms 
A total of 22 polymorphisms in 10 different genes, selected based on previous 
literature data, were analysed using different genotyping methods (Figure 3). 
Genomic DNA was extracted from peripheral EDTA-blood by the salt 
precipitation method (Aljanabi and Martinez 1997). Prior to genotyping, 
polymerase chain reaction was performed. Most of the loci of interest were 
amplified individually, except for CYP19A1 (TTTA)n and TCT Ins/Del, and the 






Figure 3. Genes and polymorphisms analysed in the present study. 
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4.2.1. PGR Alu-insertion genotyping 
Given that the three PGR polymorphisms which form the PROGINS haplotype: 
Val660Leu, His770His and the Alu-insertion, are in very strong linkage 
disequilibrium (De Vivo et al. 2002; Treloar et al. 2005a), we genotyped only 
the Alu-insertion. The presence of the 306-bp Alu-insertion was determined by 
PCR followed by gel electrophoresis. Primer sequences are given in Table 2. 
 
 
4.2.2. SNP genotyping 
SNPs in the ESR1, PGR, HSD17B1, MMP2, MMP9, VEGFA and ACE genes 
were detected using restriction fragment length polymorphism (RFLP) method. 
PCR products were digested with appropriate restriction enzymes (MBI 
Fermentas, Vilnius, Lithuania) at 37°C overnight (Table 2). All restriction frag-
ments were separated according to their lengths by gel electrophoresis and 
visualized under UV transillumination. 
The CYP19A1 C/T SNP was detected by allele-specific PCR using two 
different reverse primers (Table 2). 
All three BIRC5 promoter SNPs were amplified together in one amplicon 
and were detected by direct Sanger sequencing on an ABI 3130xl Genetic 
Analyzer (PE Applied Biosystems, Foster City, CA, USA). 
 
 
4.2.3. Microsatellite analysis 
Three microsatellite repeats: ESR1 (TA)n, ESR2 (CA)n, CYP19A1 (TTTA)n, and 
the CYP19A1 TCT Ins/Del polymorphism lying 50 bp upstream from the 
(TTTA)n tract were genotyped using automated fragment analysis. Both 
CYP19A1 polymorphisms were amplified together in one PCR amplicon. For 
each microsatellite, one of the PCR primers was fluorescently labelled, enabling 
the estimation of PCR product sizes using ABI Prism 377 automated DNA 
sequencer and GeneScan 2.1 software (PE Applied Biosystems, Foster City, 
CA, USA). GeneScan 500 ROX (PE Applied Biosystems) was used as an 
internal size standard. To confirm the number of repeats obtained by automated 
analysis, direct sequencing was performed on at least 10 cases homozygous for 











Table 2. Primer sequences, enzymes used in RFLP analyses and DNA fragment sizes 
after restriction 



























































































































F: TTCTGGCTAACTGTCTGATCA  
R1: GATGAGAAATGCTCCAGAGTA  
R2: GATGAGAAATGCTCCAGAGTG 
Allele-specific PCR 
BIRC5 -241C/T,  






S: GAACTCCAGGACTCAAGTGA Direct sequencing 
PGR Alu Ins/Del F: GCCTCTAAAATGAAAGGCAGAAAGC
R: GCGCGTATTTTCTTGCTAAATGTCTG
PCR 
ESR1 (TA)n F: AGACGCATGATATACTTCACC 
R: TAMRA-CCTACAACTCGATCTTCTCG
Automated fragment analysis 
ESR2 (CA)n F: FAM-GAGGTAAACCATGGTCTGTACC
R: GTTGAATGAGTGGGCCTCCCT 
Automated fragment analysis 
CYP19A1 (TTTA)n,  
TCT Ins/Del 
F: JOE-  
     GGTAAGCAGGTACTTAGTTAGCTA 
R: CAAGGTCGTGAGCCAAGGTC 
Automated fragment analysis 




4.3. Anti-survivin antibody detection 
Sera were collected from 98 endometriosis patients and 47 women from the 
control group B. Serum anti-survivin antibodies were detected by enzyme 
linked immunosorbent assay (ELISA). A specific ELISA Kit for Human Anti-
survivin Antibody (Uscn Life Science Inc, Wuhan, China) was used according 
to the manufacturer’s protocol. Optical density (OD) of samples was measured 
spectrophotometrically at wavelengths of 450 nm and 540 nm. Each sample was 
tested in duplicate and the mean OD value was used for further analysis. 
Intertest variability was corrected using the values of standard dilutions 
provided with the kit and of the sera used as internal controls. 
 
 
4.4.  Statistical analysis 
Data were analysed using SPSS Statistics 17 and PASW Statistics 18 (SPSS 
Inc, Chicago, IL, USA). All SNPs and Ins/Del polymorphisms were tested for 
deviation from Hardy-Weinberg equilibrium. Frequencies of nominal variables 
were compared with Pearson χ2 test. Continuous variables were analysed using 
student’s t test, in case of normal distribution, and Mann-Whitney U test, in 
case of deviation from normal distribution. The effect of various genotypes on 
endometriosis risk was evaluated by logistic regression analysis with possible 
confounding factors included in the model. 
In the analyses of microsatellites, all alleles were designated short (S) or 
long (L) either according to the naturally occurring bimodal distribution in case 
of the ESR1 (TA)n (S ≤ 17 TA and L > 17 TA repeats) and CYP19A1 (TTTA)n 
repeats (S ≤ 9 TTTA and L > 9 TTTA repeats), or using the median number of 
repeats as the cut-off in case of the ESR2 (CA)n locus (S ≤ 22 CA and L > 22 
CA repeats). 
Haplotype analyses were performed with Phase software, version 2.1 
(Stephens et al. 2001; Stephens and Scheet 2005) and Haploview program, 
version 4.0 (http://www.broad.mit.edu/mpg/haploview) (Barrett et al. 2005). 
One thousand permutations were performed for each haplotype analysis. 
A p value < 0.05 was considered statistically significant. Bonferroni-Holm 





5.1. General characteristics of study groups (Papers I, II) 
General characteristics of different study groups are given in Table 3. When 
compared to the population controls (group A), endometriosis patients were 
significantly taller (t test, p < 0.0005; OR = 1.06 for 1 cm increase in height, 
95% CI 1.02 – 1.11, p = 0.003), had a lower body mass index (BMI) (Mann-
Whitney U test, p < 0.0005; OR = 0.92 for 0.1 kg/m2 increase in BMI, 95%  
CI 0.85 – 1.01, p = 0.074) and mean age at menarche (Mann-Whitney U test,  
p = 0.003; OR = 0.80 for 1 year increase in age at menarche, 95% CI 0.67 – 
0.95, p = 0.009). Active smoking was less frequent among endometriosis 
patients and was associated with a lower disease risk (χ2-test, p < 0.0005; active 
smoking vs. non-smoking: OR = 0.37, 95% CI 0.21 – 0.63, p < 0.0005) (Table 3). 
All these differences remained statistically significant also when patients 
were compared to the combined control group A + B (Table 3). Between the 
groups used in the study of anti-survivin antibodies (98 endometriosis patients 
and control group B), similar tendencies were observed, but none of them 
reached statistical significance. 
Of the 150 endometriosis patients, 104 (69.3%) were infertile: 53 women 
(51.0%) had primary and 51 women (49.0%) had secondary infertility (a patient 
was considered infertile if she had not conceived after one year of 
contraceptive-free intercourse). When patients were classified based on disease 
severity, infertility was significantly more frequent among women with stage  
I-II endometriosis than in those with stage III-IV disease (84.8% vs. 44.8%,  
p < 0.0005). 
In further analysis, to assess the effect of various genotypes on endo-
metriosis risk, all logistic regression models were adjusted for height and 
smoking status, as possible confounding factors. Since height and BMI are 
correlated with each other, only height was included as it is more constant 
during a woman’s lifetime. Age at menarche was not used as this data was not 





Table 3. General characteristics of endometriosis patients and control groups A and B 
 Patients
(n = 150) 
Control 
group A 
(n = 199) 
Control 
group B 
(n = 47) 
Control 
group A+B 
(n = 243) 
p-valuea 
Height (cm) 






167.7  6.6 
 
165.8  5.7 
 
0.027b 
BMI (kg/m2)  




22.5  1.8 
 
22.7  4.1 
 




(mean  SD) 
 
13.0  1.4 
 
13.5  1.4 
 
13.5  1.5 
 
13.5  1.4 
 
0.003c 
Smoking (%, n) 
 Active smokers 











a Patients vs. control group A+B; b t test; c Mann-Whitney U test; d patients n = 113; e χ2-test 
 
 
5.2. Genetic variation and susceptibility to  
endometriosis (Papers I - IV) 
5.2.1. Variation in genes involved in biosynthesis and  
signalling of sex steroids 
To evaluate the role of genes involved in biosynthesis and signalling of sex 
steroids in susceptibility to endometriosis nine different polymorphisms in the 
ESR1, ESR2, PGR, CYP19A1 and HSD17B1 genes were genotyped in women 
with endometriosis and in population controls (group A). All SNPs and Ins/Del 
polymorphisms were in HWE. 
No significant differences were observed in genotype frequencies between 
patients and controls for the following polymorphisms: ESR1 PvuII T/C, PGR 
+331G/A, PGR Alu Ins/Del, CYP19A1 C/T, CYP19A1 TCT Ins/Del, and 
CYP19A1 (TTTA)n (Table 4). 
The HSD17B1 +1954A/G SNP AA and AG genotypes were more common 
among women with endometriosis than in the control group (84.7% vs. 72.9%, 
p = 0.008), and were associated with a higher disease risk (adjusted OR = 2.39, 
95% CI 1.35 – 4.21, p = 0.003). However, when patients were divided 
according to disease severity, the AA and AG genotypes were only more 
frequent among patients with stage I–II endometriosis (90.2%; adjusted  
OR = 3.89, 95% CI 1.79 – 8.45, p = 0.001), while in women with stage III–IV 
disease, their frequency (75.9%) was similar to the control group. Given that the 
majority of patients with stage I–II endometriosis suffered from infertility, 
genotype distribution was analysed also based on the fertility status of study 
subjects, revealing an association with infertility. The AA and AG genotypes 
were more common among infertile women with endometriosis (88.5%; 
adjusted OR = 3.32, 95% CI 1.65 – 6.68, p = 0.001), while in patients who did 
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not complain of infertility their frequency (76.1%) was comparable to control 
subjects.  
Analysis of the ESR1 (TA)n microsatellite revealed that women carrying 
alleles with a higher number of TA repeats were apparently more at risk for 
endometriosis, since the LL and SL genotypes were more frequent among 
patients than in the control group (70.0% vs. 56.8%, p = 0.012), increasing the 
overall disease risk (adjusted OR = 1.79, 95% CI 1.12 – 2.83, p = 0.014). 
However, similarly to the HSD17B1 +1954A/G SNP, further analysis revealed 
that these genotypes were only associated with stage I–II endometriosis 
(frequency 73.9%; adjusted OR = 2.38, 95% CI 1.35 – 4.21, p = 0.003), while in 
patients with stage III–IV disease, their frequency (63.8%) was only slightly 
higher than in the control group. Likewise, dividing patients according to their 
fertility status showed that the LL and SL genotypes were more common in 
women with infertility (74%; adjusted OR = 2.19, 95% CI 1.28 – 3.73,  
p = 0.004), whereas in patients without infertility their frequency (60.9%) was 
similar to the control group. 
Within the ESR2 gene, lower number of CA repeats correlated with a higher 
endometriosis risk. The SS homozygous genotype was more common in the 
endometriosis group than in controls (48.7% vs. 36.7%, p = 0.025; adjusted  
OR = 1.65, 95% CI 1.06 – 2.56, p = 0.028), and contrary to the abovementioned 
polymorphisms, it was more frequent among women with stage III–IV disease 
(55.2%; adjusted OR = 2.10, 95% CI 1.15 – 3.81, p = 0.015) and in patients 
without infertility (67.4%; adjusted OR = 3.56, 95% CI 1.78 – 7.10,  
p < 0.0005). Among patients with stage I-II endometriosis or in those who 
suffered from infertility, the SS genotype frequency (44.6% and 40.4%, 
respectively) was similar to controls. 
Given that in this sub-study, besides comparing general characteristics of 
subjects, also several independent genes and polymorphisms were analysed, 
Bonferroni-Holm correction for multiple comparisons was used. After applying 
this correction, all the aforementioned associations of the HSD17B1 +1954A/G 
SNP with endometriosis and infertility remained statistically significant. In case 
of the ESR1 (TA)n locus, associations with stage I–II disease and with infertility 
in endometriosis patients reached statistical significance, while for the ESR2 






Table 4. Genotype frequencies of ESR1, ESR2, PGR, HSD17B1 and CYP19A1 
polymorphisms in endometriosis patients and controls 
Genotype Patients 
(n = 150) 
% (n) 
Controls 
(n = 199) 
% (n) 
p-valuea 
ESR1 PvuII T/C 
  TT 
  CT 











  GG 
  AG 











  GG 
  AG 










PGR Alu Ins/Del 
  DelDel 
  InsDel 











  TT 
  CT 











  InsIns 
  InsDel 











  SS 
  SL 











  SS 
  SL 











  SS 
  SL 














5.2.2. Variation in matrix metalloproteinase genes 
To investigate the role of matrix metalloproteinase genes in predisposition to 
endometriosis four SNPs in the MMP2 and MMP9 promoter regions were 
genotyped in endometriosis patients and in population controls (group A). All 
genotype frequencies were in HWE. 
No significant differences were found in genotype frequencies of the MMP2 
-790T/G and the -1575G/A SNPs between patients and controls (Table 5). 
However, MMP2 -735CC genotype was significantly more frequent among 
women with endometriosis than in control individuals (82.7% vs. 71.4%,  
p = 0.014) and was associated with an increased disease risk compared to TT 
and CT genotypes (adjusted OR = 1.95, 95% CI 1.13 – 3.35, p = 0.016). When 
patients were divided based on disease stage, a stronger relation between the CC 
genotype and stage I-II endometriosis was observed (frequency 84.8%; adjusted 
OR = 2.26, 95% CI 1.17 – 4.38, p = 0.015), while the effect on stage III–IV 
disease risk did not reach statistical significance (frequency 79.3%; adjusted  
OR = 1.57, 95% CI 0.76 – 3.24, p = 0.219). No differences were observed in 
genotype frequencies between fertile and infertile patients. 
 
 
Table 5. Genotype frequencies of MMP2 and MMP9 polymorphisms in endometriosis 
patients and controls 
Polymorphism Patients 
(n = 150) 
% (n) 
Controls 




  GG 
  GA 












  TT 
  TG 












  CC 
  CT 












  CC 
  CT 















Haplotype analyses revealed that all three MMP2 promoter region SNPs were in 
strong linkage disequilibrium (LD) and formed a single haploblock (Figure 4). 
Six different haplotypes with a frequency of > 1% were defined (Table 6). The 
most common haplotype -1575G/-790T/-735C was significantly more frequent 
among patients than in controls (65.8% vs. 56.9%, p = 0.016), but after the 
permutation test (n = 1000) it no longer reached statistical significance. Three 
haplotypes: -1575G/-790T/-735T, -1575G/-790G/-735C and -1575A/-790T/ 
-735C occurred more often in the control group than in endometriosis patients, 
but  after permutation test these differences remained statistically significant 




Figure 4. Haploblocks analysed in the present study: A) MMP2 promoter haploblock  
-1575G/A, -790T/G, -735C/T; B) VEGFA haploblock -2578A/C, -1154G/A, -634G/C;  
C) ACE haploblock -240A/T, +2350A/G. 
 
 












G T C 65.8 56.9 0.016 / 0.148 
A G C 25.1 21.3 0.256 
G T T 8.3 13.1 0.049 / 0.282 
G G C 0.1 3.4 0.002 / 0.019 
A T C 0.1 3.3 0.002 / 0.011 
G G T 0.6 1.7 0.196 




The distribution of MMP9 -1562C/T SNP genotypes was similar in patients and 
control subjects (Table 5). However, more detailed analysis revealed that the  
-1562TT genotype markedly increased the risk of stage III–IV endometriosis  
in comparison to the CC genotype (TT genotype frequency 6.9% vs.  
1.5% in controls; adjusted OR = 7.73, 95% CI 1.53 – 38.90, p = 0.013). Also 
the combination of TT and CT genotypes was associated with an elevated risk 
of stage III–IV disease (TT + CT genotype frequency: 41.4% vs. 26.6% in 
controls; adjusted OR = 2.04, 95% CI 1.09 – 3.83, p = 0.027). Genotype 
frequencies were compared also in patients with and without infertility, but no 
significant differences were observed. 
 
 
5.2.3. Variation in genes involved in angiogenesis 
Four SNPs in the VEGFA gene and two SNPs in the ACE gene were genotyped 
and their respective haplotypes were analysed in endometriosis patients and in 
population controls (group A). The genotypic distribution of all VEGFA SNPs 
and of ACE +2350A/G SNP were in HWE, while the ACE -240A/T SNP 
showed a slight deviation (p = 0.02) from the HWE in the control group. 
Both ACE SNPs and three VEGFA SNPs, -1154G/A, -634G/C and +936C/T, 
were distributed similarly in women with and without endometriosis (Table 7). 
Genotype frequencies remained comparable to controls also when patients were 
divided into subgroups of stage I–II and stage III–IV disease or based on their 
fertility status. 
The VEGFA -2578A/C SNP CC genotype was significantly less common 
among patients than in controls (12.0% vs. 25.1%, p = 0.002) and was 
associated with a lower risk of endometriosis compared to the AA genotype 
(adjusted OR = 0.40, 95% CI 0.20 – 0.78, p = 0.007). When genotype 
distribution was analysed in different disease stages, similar results were 
obtained: compared to AA homozygous women, CC genotype carriers had a 
lower risk of stage I–II endometriosis (CC genotype frequency 14.1%; adjusted 
OR = 0.43, 95% CI 0.20 – 0.90, p = 0.026) and showed borderline risk 
reduction for stage III–IV disease (CC genotype frequency 8.6%; adjusted  
OR = 0.34, 95% CI 0.12 – 1.00, p = 0.050). However, after correcting for 
multiple testing only the association with the overall endometriosis risk 





Table 7. Genotype frequencies of VEGFA and ACE polymorphisms in endometriosis 
patients and controls 
Polymorphism Patients 
(n = 150) 
% (n) 
Controls 




  AA 
  AC 












  GG 
  GA 












  GG 
  GC 












  CC 
  CT 












  AA 
  AT 












  AA 
  AG 














Haplotype analysis revealed that three VEGFA SNPs (-2578A/C, -1154G/A and 
-634G/C) were in strong LD and formed a single haploblock (Figure 4). The 
VEGFA +936C/T SNP was in low LD with other SNPs (D' < 0.2). Six different 
haplotypes with a frequency of > 1% were defined (Table 8). The most common 
haplotype -2578A/-1154A/-634G showed a higher frequency among women 
with endometriosis than in the control group (40.2% vs. 31.6%, p = 0.018), but 
after the permutation test (n = 1000) it no longer reached statistical significance. 
Instead, one rare haplotype -2578C/-1154A/-634G was more frequent among 
controls compared to endometriosis patients (3.0% vs. 0.4%, p = 0.012), but 
again, after the permutation test this difference became statistically in-
significant. All other VEGFA haplotypes were distributed equally between 
















A A G 40.2 31.6 0.018 / 0.071 
C G C 18.4 22.1 0.231 
C G G 18.1 21.1 0.322 
A G G 21.4 17.9 0.248 
C A G   0.4   3.0 0.012 / 0.052 
A G C   0.4   2.0 0.067 
a χ2 test; p-value: before / after permutation test (n = 1000) 
 
 
The two ACE SNPs (-240A/T and +2350A/G) were in strong LD (Figure 4). 
Four different haplotypes were defined (Table 9). The most rare haplotype  
-240T/+2350A was more prevalent in the control group than among patients 
(3.7% vs. 0.8%, p = 0.014). However, the permutation test (n = 1000) rendered 
this result statistically insignificant. 
 
 










A A 49.6 49.9 0.904 
T G 34.2 29.0 0.090 
A G 15.4 17.4 0.332 
T A   0.8   3.7 0.014 / 0.055 
a χ2 test; p-value: before / after permutation test (n = 1000) 
 
 
5.2.4. Variation in survivin gene 
To assess the role of the BIRC5 gene in susceptibility to endometriosis, three 
promoter region polymorphisms were genotyped in endometriosis patients  
(n = 149) and in control groups A (n = 196) and B (n = 47). All three SNPs 
were in HWE. 
All genotype frequencies of the -241C/T, -235G/A and -31G/C SNPs were 
similar among patients and in population controls (group A) (Table 10). 
Differences in genotypic distribution remained statistically insignificant also 
after dividing patients based on disease severity (stage I–II and stage III–IV 
42 
 
disease) or their fertility status. In the control group B, genotype frequencies 
were slightly different than in women with endometriosis, however these 
differences did not reach statistical significance for any of the SNPs (Table 10). 
 
 
Table 10. Genotype frequencies of BIRC5 polymorphisms in endometriosis patients and 
control groups A and B 
Polymorphism Patients 




(n = 196) 
% (n) 
p-valuea Control  
group B 




  CC 
  CT 

















BIRC5 -235G/A  
  GG 
  GA 


















  GG 
  GC 




















5.3. Immunoreactivity to survivin (Paper IV) 
5.3.1. Anti-survivin autoantibodies and endometriosis 
To determine if women with endometriosis show increased autoimmunity 
against survivin, and whether this could facilitate the detection of endometriosis 
in a non-invasive manner, sera from 98 endometriosis patients (55 women with 
stage I–II and 43 with stage III–IV endometriosis) and 47 women from control 
group B were tested for anti-survivin autoantibodies. Women from group B 
were selected for antibody analysis because they were of the same age as 
endometriosis patients (30.0  6.1 vs. 30.9  6.5 years, respectively,  
p > 0.05), presented with similar gynaecological symptoms and were proved to 
be endometriosis-free by laparoscopic surgery. 
Anti-survivin antibody levels did not differ significantly between study 
groups; median OD values were 0.078 and 0.119 for patients and controls, 
respectively (p > 0.05). Autoantibody levels were similar also in patients with 
stage I–II (median OD: 0.074) and stage III–IV (median OD: 0.104) endo-
metriosis. Since the control group B and endometriosis patients differed 
slightly, though insignificantly, in the prevalence of infertility (74.5% vs. 
59.2%, respectively, p > 0.05), anti-survivin antibody levels were compared 
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also in fertile and infertile women, but no significant differences were observed 
(median OD values: 0.097 vs. 0.080, respectively, p > 0.05). 
Interestingly, anti-survivin autoantibody levels seemed to be influenced by 
the smoking status of study subjects. Analysing together all patients and 
controls, significantly lower median OD values were found in sera of actively 
smoking women (n = 32) compared to non-smokers (n = 113) (0.019 vs. 0.155, 
respectively; p < 0.0005). This correlation remained statistically significant also 
when patients and controls were analysed separately. 
Since smoking seemed to influence autoantibody level, comparison of 
median OD values in endometriosis patients and controls was repeated in-
cluding only non-smoking women (79 patients and 34 controls), which con-
firmed that anti-survivin antibodies were not associated with endometriosis 
(median ODs 0.146 vs. 0.187, respectively; p > 0.05). 
 
 
5.3.2. Anti-survivin autoantibodies and variation in survivin gene 
To determine whether anti-survivin antibody levels are influenced by genetic 
variation in the survivin gene, correlations between BIRC5 promoter SNPs and 
autoantibody levels were evaluated among all non-smoking study participants. 
No significant associations between the three promoter region SNPs  
(-241C/T, -235G/A, -31G/C) and median autoantibody levels were found. 
However, further analysis on elevated antibody concentrations (OD ≥ 1.0 or  
OD ≥ 2.0) revealed an association between the -235G/A SNP and high OD 
values. The GA genotype was significantly more frequent among women with 
the highest antibody level (OD ≥ 2.0) compared to those with a lower level  




Endometriosis is considered to be a complex trait, caused by the interaction of 
genetic and environmental factors. To identify the genes involved in disease 
development, numerous candidate gene studies and a few genome-wide 
investigations have been carried out, but our knowledge in this field is still 
incomplete. Since genetic susceptibility markers may vary in different popu-
lations, our aim was to investigate possible associations between endometriosis 
and some of the plausible candidate genes in the Estonian population. 
For this purpose, we enrolled in the present study women with confirmed 
endometriosis, fertile women with no medical history of endometriosis as 
population controls and patients who had undergone laparoscopy and were 
found to be endometriosis-free as gynaecological controls. The selection of 
controls for studies on endometriosis is complicated since surgery is needed for 
the definite exclusion of endometriosis. When women are enrolled from the 
general population based on their self-reported medical history, some un-
diagnosed cases might be included in the control group, making it more difficult 
to detect weak associations. Then again, using women who have undergone 
gynaecological surgery and are proved to be endometriosis-free might form a 
slightly biased control sample, as they generally suffer from some other 
gynaecological disorder. Therefore, it might be best, if both types of controls 
were used. In the present study, however, we decided to concentrate mainly on 
the population control group. 
 
 
6.1. Endometriosis and general characteristics  
of study subjects 
Epidemiological studies on endometriosis have revealed several factors which 
could increase disease risk, including dysmenorrhea (as an indicator of stronger 
uterine contractions and increased retrograde menstruation), younger age at 
menarche and shorter cycle length, heavy menstrual flow, nulliparity, increased 
height and lower weight and BMI (Cramer and Missmer 2002; McLeod and 
Retzloff 2010). Also certain life style habits, like cigarette smoking or alcohol 
and caffeine consumption, might decrease or increase, respectively, the risk of 
developing endometriosis (McLeod and Retzloff 2010). 
In accordance with previous literature reports, assessment of the data 
gathered on our study subjects revealed similar findings. A positive association 
was observed between endometriosis and height, while BMI was negatively 
correlated with disease risk. In addition, lower age at menarche was related to a 
higher risk of endometriosis, whereas active cigarette smoking seemed to have a 
protective effect. 
Within the patients group, the occurrence of infertility was significantly 
higher among women with stage I–II endometriosis than in those with stage III–
IV disease. However, it probably does not reflect a true association between the 
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disease stages and fertility status, as advanced endometriosis seems to correlate 
with higher rates of infertility (Albertsen et al. 2013). Therefore, it is more 
likely caused due to a diagnostic bias. Given that in the present study women 
who underwent laparoscopy for a suspected endometriosis or for infertility were 
enrolled, it is possible that among infertile patients milder asymptomatic forms 
of endometriosis were diagnosed, which normally would remain undiscovered.  
 
 
6.2. Genetic variation influencing susceptibility  
to endometriosis 
6.2.1. Variation in genes involved in biosynthesis and  
signalling of sex steroids 
Considering the importance of oestrogen in the development of endometriosis 
(Kitawaki et al. 2002), we aimed to investigate whether genes involved in 
oestrogen biosynthesis and in sex steroid signalling (ESR1, ESR2, PGR, 
CYP19A1, HSD17B1) are associated with susceptibility to endometriosis in our 
study group. Since these genes might affect also female reproductive function, 
we studied their relation also to endometriosis-associated infertility. 
Of the nine polymorphisms analysed, three were found to be associated with 
endometriosis and/or infertility: ESR1 (TA)n, ESR2 (CA)n and HSD17B1 
+1954A/G. 
Within the ESR1 gene, we genotyped the PvuII T/C SNP in intron 1 and a 
(TA)n microsatellite repeat in the promoter region. Both of these poly-
morphisms have been associated with endometriosis previously, but the results 
have been inconsistent (Falconer et al. 2007). In agreement with some prior 
studies (Wang et al. 2004; Kim et al. 2005b; Renner et al. 2006; Xie et al. 
2008), we observed no association between the PvuII T/C SNP and endo-
metriosis in our cohort. This finding was confirmed also by a recent study by 
(Trabert et al. 2012) and by two meta-analyses which concluded that ESR1 
PvuII T/C SNP is not related to susceptibility to endometriosis (Hu et al. 2012; 
Li et al. 2012). We did, however, observe a correlation between ESR1 (TA)n 
genotypes containing longer (TA)n repeats (LL and SL) and an increased risk of 
stage I–II endometriosis and endometriosis with infertility. This finding differs 
from other previous reports. Studies on Greek and Korean woman showed 
shorter ESR1 (TA)n repeats to be correlated with susceptibility to endometriosis 
in general and with the risk of stage I–II disease, respectively (Georgiou et al. 
1999; Kim et al. 2005b). Instead, in Taiwanese Chinese women, associations 
were found between a higher risk of stage III–IV endometriosis and three 
different (TA)n alleles: one short repeat (14 TA) and two longer repeats (18 and 
24 TA) (Hsieh et al. 2005b). In a previous study on Estonian women exploring 
the effect of ESR1 gene variants on the outcome of ovarian stimulation in 
infertile women, no association was observed between endometriosis and the 
(TA)n locus, and conversely, shorter (TA)n repeats were found to correlate with 
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a higher risk for unexplained infertility (Altmäe et al. 2007). This contradicts 
our current results, however, it is difficult to directly compare the findings of 
these two studies due to differences in sample size and control group selection 
(fertile women in the present study and women with tubal factor infertility in 
the previous one). 
The association observed between ESR1 (TA)n repeat length and infertility 
in endometriosis patients is in agreement with a previous study on fertile 
women and patients with unexplained infertility undergoing in vitro fertilisation 
(IVF), where longer (TA)n repeats were found to correlate with an elevated risk 
of infertility and with a lower oocyte fertilisation rate in IVF procedures (Ayvaz 
et al. 2009). In addition, carriers of long (TA)n repeats have been shown to have 
an elevated risk of premature ovarian failure (POF) (Bretherick et al. 2008). 
Likewise, other ESR1 polymorphisms have been reported to influence female 
fertility (Corbo et al. 2007) and the outcome of IVF (Sundarrajan et al. 1999). 
Therefore, we cannot exclude that the ESR1 (TA)n locus is actually more related 
to female infertility and that the observed association with stage I–II 
endometriosis is merely a reflection of the high frequency of infertile women in 
this group.  
Within the HSD17B1 gene, we studied the +1954A/G SNP in exon 6, which 
revealed similar associations as the ESR1 (TA)n dinucleotide repeat. The AA 
and AG genotypes increased the overall risk of endometriosis, but the strongest 
associations were observed with stage I–II disease and infertility in endo-
metriosis patients. The +1954AA genotype has been shown to correlate with 
elevated circulating oestradiol level (Setiawan et al. 2004), and thus could 
favour the growth of endometriotic lesions. In the only prior study on this 
polymorphism and endometriosis, the AA and AG genotypes correlated with an 
increased disease risk and also with its severity, being more frequent in women 
with stage III–IV endometriosis (Tsuchiya et al. 2005). Thus the results of these 
two studies are in part inconsistent. This could be caused by differences in study 
populations and sample sizes, but also by the variation in the fertility status of 
study subjects, as Tsuchiya and colleagues (2005) enrolled only infertile 
patients and controls. Considering our results and that in the previous study a 
significant association with endometriosis was found also using infertile 
controls, the HSD17B1 +1954A/G SNP seems to be related not only with 
endometriosis or infertility, but more specifically with infertility in endo-
metriosis patients. Whether this is true and which could be the molecular 
mechanisms behind it, needs to be elucidated by future studies. 
In the ESR2 gene, we genotyped a (CA)n microsatellite repeat in intron 5, 
which seemed to influence susceptibility to endometriosis and especially the 
risk of stage III–IV disease. However, correction for multiple testing rendered 
these associations statistically insignificant, which is in accordance with the 
previous study by Altmäe et al (2007). Still, subdividing patients according to 
their fertility status revealed a correlation between endometriosis without 
infertility and homozygosity for shorter (CA)n repeats, which remained 
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significant also after applying the Bonferroni-Holm correction. Among infertile 
patients the frequency of the SS genotype was similar to controls. 
The impact of the ESR2 (CA)n locus on gene function is not clear yet, but its 
length might modify gene function. Although there is no direct correlation 
between the number of (CA)n repeats and ESR2 transcriptional activity (Ugai et 
al. 2008), it is possible that this microsatellite affects some posttranscriptional 
processes which influence ERβ expression (Hui et al. 2005). Significant up-
regulation of ERβ and down-regulation of ERα has been reported in endo-
metriotic lesions compared to eutopic endometrium (Fujimoto et al. 1999; Smuc 
et al. 2007). This leads to a decrease in ERα/ERβ ratio, suggesting that in endo-
metriotic tissue the function of oestrogens is at least to some extent mediated 
via ERβ. It has been shown that ERβ suppresses the expression of ERα in 
endometrial and endometriotic stromal cells via binding to classic and non-
classic DNA motifs in alternatively used ERα promoters (Trukhacheva et al. 
2009). As ERα stimulates the production of PR, it was hypothesized that this 
decrease in ERα/ERβ ratio could lead to the suppression of PR expression and 
to progesterone resistance which has been observed in endometriosis (Bulun et 
al. 2006). Furthermore, ERβ might contribute to the proliferation of endo-
metriotic lesions by regulating the cell cycle progression (Trukhacheva et al. 
2009). Thus, there is several evidence of the importance of ERβ in the develop-
ment of endometriosis, however, further studies are needed to clarify the exact 
role of ERβ and the ESR2 (CA)n repeat in the pathogenesis of this disease.  
We observed no associations between endometriosis or endometriosis-
associated infertility and polymorphisms in the PGR and CYP19A1 genes in the 
Estonian population. This is in agreement with several previous studies (Huber 
et al. 2005; Treloar et al. 2005a; Govindan et al. 2007; Hur et al. 2007; van 
Kaam et al. 2007; Gentilini et al. 2008b) as well as with one of the latest papers 
(Trabert et al. 2012). Also a recent meta-analysis failed to detect associations 
between endometriosis and polymorphisms in the CYP19A1 gene, however, it 
did suggest that the PGR PROGINS haplotype may play a role in the risk of 
endometriosis (Hu et al. 2012). Still, the latter conclusion might not be 
completely accurate, as several studies with negative results were not included 
in the meta-analysis. As mentioned above, Trabert and colleagues (2012) 
observed no association between endometriosis and several CYP19A1 SNPs, 
including the 3’-UTR C/T SNP investigated in the present study. Yet, they did 
find a correlation between increased risk of endometriosis and three intronic 
CYP19A1 SNPs (rs1870049, rs1004982 and rs936307), that were not included 
in the present thesis and have not been associated to endometriosis before. 
Therefore, further studies are warranted to elucidate the role of CYP19A1 





6.2.2. Variation in matrix metalloproteinase genes 
In the present study, we investigated the role of two matrix metalloproteinase 
genes, MMP2 and MMP9 in susceptibility to endometriosis. Our results 
demonstrated that two promoter region SNPs: MMP2 -735C/T and MMP9  
-1562C/T, as well as MMP2 promoter haplotypes were associated with the risk 
of endometriosis in Estonian women. 
In the only prior study investigating the MMP2 -735C/T SNP in the develop-
ment of endometriosis no significant association was found (Kang et al. 2008b). 
In contrast, we observed that women with the -735CC genotype had almost 
twice the risk of endometriosis compared to CT or TT genotype carriers and this 
association was particularly evident in case of stage I-II disease. 
Although the relationship between MMP2 -735C/T SNP and endometriosis 
is only beginning to be defined, earlier studies have reported the -735C allele to 
correlate with higher promoter activity and with an increased susceptibility to 
certain types of cancer and chronic heart failure (Vasku et al. 2003; Yu et al. 
2004). Therefore, considering these previous studies along with our results, we 
may hypothesize that the MMP2 -735CC genotype increases the risk of 
endometriosis through higher MMP2 transcriptional and enzymatic activities 
facilitating the invasion and survival of endometriotic implants in ectopic 
locations. 
The other two MMP2 SNPs, -1575G/A and -790T/G, appear to be neutral 
with no effect on promoter activity (Price et al. 2001). Indeed, they were not 
individually associated with endometriosis in the present study. This is in 
accordance with a previous paper, where a minor correlation observed with the  
-1575G/A SNP disappeared after correcting for multiple testing (Borghese et al. 
2008). 
All three MMP2 promoter SNPs were in strong LD, forming eight different 
haplotypes. The most common one, -1575G/-790T/-735C, was more frequent 
among patients, but after the permutation test it no longer reached statistical 
significance. Instead, two very rare haplotypes, -1575G/-790G/-735C and  
-1575A/-790T/-735C, were more common in the control group, suggesting a 
possible protective effect against endometriosis. This is in agreement with the 
results reported by Vašků and colleagues (2004), who found a significant 
association between the most common MMP2 haplotype (-1575G/-1306C/ 
-790T/-735C) and an elevated risk of coronary triple-vessel disease, while two 
rare ones, similar to our protective haplotypes, (-1575G/-1306C/-790G/-735C 
and -1575A/-1306C/-790T/-735C) were present only in control subjects (Vasku 
et al. 2004). 
In vitro expression studies on the MMP9 -1562C/T SNP have shown that the 
C to T transition causes the loss of a binding site for a transcription repressor 
protein, resulting in a significant increase in promoter activity (Zhang et al. 
1999). The -1562T allele has in fact been associated with tumour aggres-
siveness and invasiveness (Matsumura et al. 2005; Hughes et al. 2007; Xing et 
al. 2007). In the present study, we observed no association between this SNP 
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and the overall risk of endometriosis. However, subdividing patients according 
to disease severity, we revealed a significant correlation between the TT and CT 
genotypes and stage III–IV endometriosis. Therefore, it is possible that the 
presence of the -1562T allele renders endometrial cells particularly aggressive 
and like in cancer, where it is associated with tumour invasion and metastatic 
spread, it could favour the development of more advanced forms of endo-
metriosis. Our results, however, disagree with two previous studies which 
showed no association between the individual MMP9 -1562C/T SNP and stage 
III–IV endometriosis in Asian women (Shan et al. 2006; Han et al. 2009b). Han 
and colleagues (2009b) reported a correlation between increased endometriosis 
risk and the MMP9 -1562C/5546A haplotype, but oppositely to our findings, it 
included the -1562C allele. These discrepancies could be caused by population 
differences, therefore, further studies on Caucasian women would be needed to 
confirm our results. 
 
 
6.2.3. Variation in genes involved in angiogenesis 
We investigated the role of VEGFA and ACE gene polymorphisms and 
haplotypes in susceptibility to endometriosis and found evidence of a possible 
association with the VEGFA -2578A/C SNP. 
In our study group, the VEGFA -2578CC genotype was associated with a 
decreased risk for endometriosis when compared to AA genotype carriers. This 
finding, however, is not in accordance with other two studies that have 
investigated the role of this SNP as a genetic determinant of susceptibility to 
endometriosis. In a study on Australian women no significant association was 
observed (Zhao et al. 2008), while in Northern Chinese women, oppositely to 
our results, the -2578AA genotype decreased disease risk (Liu et al. 2009). 
Discrepancies in the results of these three studies could be caused by ethnic 
differences, as the observed allele frequencies were very diverse between 
populations. Therefore, it might be more appropriate to compare populations 
with similar allele frequencies to evaluate the role of this SNP in endometriosis. 
VEGFA -2578CC genotype has been shown to correlate with elevated serum 
VEGF levels (Steffensen et al. 2010). On the contrary, experiments on non-
small cell lung cancer demonstrated that the CC genotype was associated with 
lower VEGF expression in cancer cells and with lower vascular density 
(Koukourakis et al. 2004). In accordance with both of these studies, Szeto and 
colleagues observed that -2578CC genotype carriers presented higher circu-
lating VEGF levels but lower protein and mRNA expression level in peritoneal 
dialysis effluent, suggesting that systemic and local peritoneal VEGF produc-
tion may be differently regulated (Szeto et al. 2004). Therefore, we hypothesize 
that the -2578A/C SNP might have a similar effect on angiogenesis in endo-
metriotic implants and women with the CC genotype could have a decreased 




No association was observed between endometriosis and other VEGFA 
SNPs, -1154G/A, -634G/C and +936C/T SNPs, in Estonian women. This is in 
agreement with some previous studies, while conflicts with others. For the most 
studied SNP, -634G/C (+405G/C), contradicting results have been reported, as 
positive associations have been found both with the C allele (Kim et al. 2005a; 
Gentilini et al. 2008a; Attar et al. 2010; Emamifar et al. 2011) and the G allele 
(Bhanoori et al. 2005; Altinkaya et al. 2011), whereas others reported no 
association (Ikuhashi et al. 2007; Zhao et al. 2008; Cosin et al. 2009). The  
-1154G/A SNP has been analysed only in one study, where the AA genotype 
was found to have a protective effect against endometriosis in Northern Chinese 
women (Liu et al. 2009). For the +936C/T SNP, the T allele has been reported 
to increase the overall disease risk (Cosin et al. 2009) or risk for stage III–IV 
endometriosis (Ikuhashi et al. 2007), while others have reported no association 
(Kim et al. 2008; Zhao et al. 2008; Liu et al. 2009). Since all these studies have 
been performed in different populations, ethnic variance might be one of the 
reasons for discrepancies in results and makes it difficult to draw any firm 
conclusions about the association of these individual SNPs with endometriosis. 
Recent meta-analyses on VEGFA polymorphisms concluded that only the 
+936C/T SNP is associated with endometriosis risk (Liang et al. 2012; Xu et al. 
2012). 
There is a high degree of linkage disequilibrium among the VEGFA up-
stream SNPs, therefore we evaluated also their collective effect as a haplotype 
as it may have a stronger impact on endometriosis risk than single SNPs. In a 
previous study, some VEGFA -2578/-1154/-460 haplotypes were found to differ 
significantly in their frequency among endometriosis patients and healthy 
controls (Liu et al. 2009). Yet, another paper reported no association between 
endometriosis and -2578/-460/+405 haplotypes (Zhao et al. 2008). In agreement 
with the latter study, we observed no correlation between VEGFA haplotypes 
and the risk of endometriosis in Estonian women. 
Circulating ACE levels have been shown to be related to ACE Alu I/D,  
-240A/T and +2350A/G polymorphisms in different populations (Zhu et al. 
2001; Baghai et al. 2006; Jeunemaitre 2008). However, there are limited data 
about their relevance in the pathogenesis of endometriosis. The only two studies 
performed on Taiwan Chinese women demonstrated that the Alu-insertion,  
-240T allele and +2350G allele were all associated with an increased 
susceptibility to endometriosis (Hsieh et al. 2005a; Hsieh et al. 2007a). Since 
there is a strong linkage (r2 = 0.91) between the Alu Ins/Del and +2350A/G 
polymorphisms (Kehoe et al. 2003), only the +2350A/G and -240A/T SNPs 
were analyzed in the present study. No significant association, however, was 
observed between endometriosis and ACE SNPs, neither individually nor in 
haplotype. 
As for the VEGFA -2578A/C SNP, the discrepancy between previous and 
our results could be caused by very different allele frequencies in ethnically 
diverse study groups. The control group frequencies of the +2350G allele were 
2.2% in Taiwan Chinese women (Hsieh et al. 2005a) and 46.5% in Estonian 
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women. Similarly, the frequencies of the -240T allele were 18.2% and 31.7%, 
respectively. It has been shown previously that important ethnic variation in the 
genetic regulation of serum ACE activity may exist (Bloem et al. 1996). In 
addition, there was a significant deviation from HWE (p = 0.0007) in the 
+2350A/G genotype distribution and a borderline deviation (p = 0.049) in the  
-240A/T SNP frequency among the control group in the Hsieh et al. (2005) 
study, which might have influenced their results to some extent. 
There was a slight deviation from HWE (p = 0.02) also in our control group 
for the ACE -240A/T SNP. Since we ruled out genotyping errors, it might be 
that for some reason this locus is under selection and has an effect on fertility as 
our control group consisted solely of fertile women. However, comparing  
-240A/T genotype frequencies among fertile and infertile patients revealed no 
significant difference in our cohort. Therefore, it is difficult to say whether the 
selection is the principal cause of divergence from HWE in our control group. 
Similarly to our study, however, also Baghai et al. (2006) found different ACE 
promoter SNPs, including the -240A/T, to deviate significantly from HWE in 
healthy controls. 
Considering the very small number of studies on ACE polymorphisms and 
endometriosis and their discordant results, future studies in genetically more 
homogeneous populations would be helpful to clarify the role of ACE gene in 
the pathogenesis of endometriosis. 
 
 
6.2.4. Variation in survivin gene 
Considering the importance of survivin in normal endometrial functioning 
(Nabilsi et al. 2010), its over-expression in endometriotic tissue (Ueda et al. 
2002), and the reduced apoptotic properties of endometriotic cells, BIRC5 
seems an attractive candidate gene for an endometriosis susceptibility study.  
To evaluate possible associations between endometriosis and survivin, we  
analysed the distribution of three BIRC5 promoter region polymorphisms:  
-241C/T, -235G/A and -31G/C in endometriosis patients and in two different 
control groups, population controls (group A) and gynaecological controls 
(group B). Although these polymorphisms appear to influence survivin 
expression (Xu et al. 2004; Jang et al. 2008; Wagner et al. 2008; Boidot et al. 
2010; Kawata et al. 2011), in the present study, no significant difference was 
observed in their genotype frequencies between patients and the two control 
groups. Genotype distributions were similar also in stage I–II and stage III–IV 
disease, suggesting that an association between BIRC5 promoter SNPs and 
susceptibility to endometriosis is unlikely in Estonian women. Since this is the 
first study about survivin polymorphisms and endometriosis, further studies in 





6.3. Immunoreactivity to survivin 
6.3.1. Anti-survivin autoantibodies and endometriosis 
Survivin expression is increased in neoplastic tissues and several studies have 
shown that the concentration of anti-survivin antibodies is elevated in sera of 
cancer patients (Rohayem et al. 2000; Eto et al. 2007; Söling et al. 2007). Since 
endometriotic cells express more survivin than normal endometrial cells (Ueda 
et al. 2002; Fujino et al. 2006; Watanabe et al. 2009), we aimed to detect if this 
stimulates humoral immunoreactivity to survivin and whether antibodies against 
survivin could be used as a diagnostic marker to distinguish endometriosis 
patients from women with similar complaints but without the disease. 
Anti-survivin autoantibody levels were measured in the sera of endo-
metriosis patients and of gynaecological controls (group B), but no significant 
difference was observed. In addition, antibody levels were not influenced by 
disease stage nor by the fertility status. Thereby, according to our data, anti-
survivin antibodies cannot be used as a biomarker for endometriosis. 
Some studies on cancer patients have shown that anti-survivin antibody 
concentrations are not directly correlated with survivin expression levels in 
tumour tissues (Söling et al. 2007; Karanikas et al. 2009). This might explain, to 
some extent, why we observed no significant difference in anti-survivin 
antibody levels between women with and without endometriosis. On the other 
hand, as survivin is also expressed in normal endometrium, the increase in its 
expression in endometriotic lesions might not be sufficient to induce a stronger 
autoimmune response than in healthy women. 
Although this was not the aim of our study, while analysing possible con-
founding factors, we observed a significant negative correlation between active 
smoking and serum anti-survivin antibody levels. This finding contradicts the 
results from a previous study (Rom et al. 2010), where healthy non-smoking 
controls had lower median anti-survivin antibody levels than heavy smokers. 
However, compared to our study, the enrolled individuals were considerably 
older, the study groups included individuals from both sexes, and most of the 
smokers had also had long-term asbestos exposure (Rom et al. 2010). We 
cannot exclude that some of these parameters may have had a modulating effect 
on the anti-survivin immunogenic response. 
Cigarette smoking is known to cause alterations in the immune system 
leading to heightened constitutive inflammation, impaired responses to patho-
gens, suppressed anti-tumour activity and abnormal adaptive Th17 immunity. 
However, it is difficult to correlate reduced anti-survivin autoantibody levels 
directly with smoking, as in general it tends to favour autoimmune responses 
(Arnson et al. 2010; Lee et al. 2012). Therefore, other indirect mechanisms 
could be involved. Since our study group consisted only of premenopausal 
women, lower antibody levels in active smokers might be caused by the anti-
oestrogenic effect of cigarette smoking. It has been shown that women who 
smoke have lower oestrogen levels than non-smoking women (Shiverick and 
Salafia 1999; Soldin et al. 2011) and that oestrogens stimulate survivin 
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expression in the endometrium and in oestrogen-sensitive cancer cells (Frasor et 
al. 2003; Nabilsi et al. 2010). Therefore, the anti-oestrogenic effect of smoking 
could lead to a reduction in survivin expression and thus to a lower autoimmune 
reactivity against it. However, additional research in larger study groups is 
required to fully reveal the impact of smoking on immunoreactivity to survivin. 
 
 
6.3.2. Anti-survivin autoantibodies and variation in survivin gene 
Polymorphisms in the coding region of a gene may influence the production of 
autoantibodies against the protein encoded by this gene, as has been shown for 
example for the zinc transporter 8 (ZnT8) gene. ZnT8 is a major target of 
autoimmunity in type 1A diabetes and the gene encoding for it, SLC30A, 
contains a nonsynonymous SNP Arg325Trp, which defines one of the protein’s 
antigenic epitopes and thus determines the production of specific autoantibodies 
recognizing either 325Arg residue or the 325Trp residue (Wenzlau et al. 2008). 
In the present study, only non-coding BIRC5 SNPs were included, therefore, 
associations between anti-survivin autoantibodies and possible structural 
changes in survivin could not be assessed. However, as protein expression 
might be influenced by promoter region polymorphisms, we wanted to evaluate 
the effect of BIRC5 -241C/T, -235G/A and -31G/C SNPs on the serum level of 
anti-survivin antibodies. Considering that smoking status was the major con-
tributor to autoantibody concentrations, associations between BIRC5 SNPs and 
anti-survivin antibodies were evaluated only among non-smoking women. No 
significant correlation was revealed between BIRC5 genotypes and median 
antibody levels, but a positive association was observed between the -235A 
allele and higher autoantibody concentrations (OD ≥ 2.0). Still, this result 
should be considered with caution, as the -235A allele frequency was very low 
in our study group. 
It is difficult to speculate on the biological background of this finding due to 
the scarce and inconsistent data about the impact of the -235G/A SNP on 
survivin expression. In in vitro gene reporter assays the -235G/A SNP has been 
shown to have no effect on survivin promoter activity (Xu et al. 2004; Wagner 
et al. 2008). However, in a recent study on breast carcinomas, a strong 
association between the A allele and increased survivin mRNA level was 
detected (Boidot et al. 2010). The -235G/A SNP seems to create a second 
binding-site for the transcription factor GATA-1 in the survivin promoter, 
which could explain increased gene expression in the presence of the -235A 





Endometriosis is a complex gynaecological disease and is often associated also 
with infertility. It is caused by the interplay of different factors, including 
individual’s genetic variations. Since the aethiopathogenesis of endometriosis is 
not fully understood yet, identifying genes that contribute to disease risk might 
help determine biological pathways and mechanisms involved in endometriosis 
development. Numerous association studies on plausible candidate genes have 
been carried out in various populations, reporting different risk alleles for 
endometriosis. In the present study we evaluated associations between endo-
metriosis and ten different genes, which were selected based on their plausible 
role in disease development. As endometriosis is considered to be an oestrogen-
dependent disease, five genes involved in sex steroid biosynthesis and signal-
ling were included, while the other five genes participating in tissue remodel-
ling, angiogenesis and apoptosis were chosen in view of the Sampson’s implan-
tation theory. Since the role of genetic factors in the development of endo-
metriosis-associated infertility has received little attention thus far, all the 
studied variants were also evaluated in relation to the fertility status of our study 
subjects. 
In addition, the presence of anti-survivin autoantibodies was analyzed in 
women with and without endometriosis, to assess whether it could be used as a 
possible disease marker for minimally invasive diagnosis. 
 
Based on our result we can make the following conclusions: 
 
1. Genetic variation in genes involved in sex steroid biosynthesis and 
signalling may influence both, susceptibility to endometriosis as well as 
infertility. More specifically, we showed that HSD17B1 +1954A/G SNP 
and ESR2 (CA)n repeat are associated with endometriosis with and 
without infertility, respectively, while the ESR1 (TA)n locus appears to be 
more related to infertility. 
 
2. Polymorphisms in matrix metalloproteinase genes MMP2 and MMP9 
correlate with endometriosis risk. We showed that the MMP2 -735C/T 
SNP and certain MMP2 promoter haplotypes are associated with overall 
risk of endometriosis, while the presence of MMP9 -1562C/T SNP 
increases susceptibility to advanced stages of endometriosis. 
 
3. Variation in the VEGFA gene may influence susceptibility to endo-
metriosis, while ACE polymorphisms are unlikely to affect disease risk. 
We showed that the VEGFA -2578A/C SNP is associated to overall 
endometriosis risk. 
 
4. Variations in the BIRC5 gene promoter area do not influence sus-




5. Autoimmune reactivity against survivin is similar in women with and 
without endometriosis, as was revealed by the detection of autoanti-
bodies. Therefore, anti-survivin antibodies cannot be used as a biomarker 
of endometriosis. However, anti-survivin antibody concentration appears 
to be influenced by the BIRC5 -235G/A SNP and by cigarette smoking, 
showing their general importance. 
 
In conclusion, this study identified a set of the genetic markers associated with 
susceptibility to endometriosis in Estonian women, and it is the first report to 
show a significant correlation between the ESR2 (CA)n repeat length and 
endometriosis risk. Interestingly, some polymorphisms showed different distri-
bution in patients with or without infertility. As different mechanisms have been 
suggested to be involved in the development of stage I–II and stage III–IV 
disease, the same could be hypothesized about endometriosis with and without 
infertility. Therefore, fertility status of endometriosis patients is an aspect that 
should deserve more attention in future studies, to clarify the role of genetic 
factors and related proteomic changes in the pathogenesis of endometriosis and 
infertility associated with it.  
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SUMMARY IN ESTONIAN 
Endometrioosi geneetiline eelsoodumus 
Endometrioos on krooniline günekoloogiline haigus, mille korral näärme- ja 
stroomarakkudest koosnev endomeetriumi taoline kude paikneb kolletena 
väljaspool emakaõõnt, peamiselt vaagna piirkonna peritoneumil, munasarjades 
ning uterosakraalligamendil. Harvem võib haiguskoldeid esineda ka kuseteedes, 
soolestikus, kopsudes jne. Vastavalt kollete asukohale, arvule, sügavusele ning 
liitelise protsessi ulatusele jagatakse endometrioos nelja staadiumisse: I –  
minimaalne, II – kerge, III – mõõdukas ja IV – raske. Endometrioosi peamisteks 
sümptomiteks on krooniline vaagnapiirkonna valu, düsmenorröa, düspareuunia 
ning sageli kaasneb haigusega ka viljatus. Endometrioosi on võimalik kindlalt 
diagnoosida ainult laparoskoopial/laparotoomial visuaalse leiu ja histoloogilise 
uuringu tulemuse põhjal. Mitteinvasiivse diagnostikameetodi puudumise tõttu 
on raske hinnata haiguse täpset esinemissagedust, kuid arvatakse, et ligikaudu 
10% reproduktiivses eas olevatest naistest põeb endometrioosi. Viljatute naiste 
seas on esinemissagedus veelgi kõrgem, ulatudes kuni 50% juhtudest. 
Endometrioosi tekkepõhjused ei ole veel selged. Välja on pakutud erinevaid 
hüpoteese, millest kõige levinum on implantatsiooniteooria. Selle kohaselt tekib 
endometrioos menstruaalvere retrograadsel liikumisel läbi munajuhade kõhu-
õõnde sattunud endomeetriumi rakkudest, mis kinnituvad peritoneumile ning 
lokaalse verevarustuse tekkimisel arenevad endometrioosi kolleteks. Selles 
protsessis on oluline roll ensüümidel, mis osalevad ekstratsellulaarse maatriksi 
remodelleerimises, nagu näiteks maatriksi metalloproteinaasid (MMPd) ning 
angiogeneesi stimuleerivatel faktoritel. Lisaks eelnevale, võib kollete kasvu 
soodustada ka endomeetriumi rakkude langenud apoptootiline aktiivsus. 
Kuna menstuaalverd satub kõhuõõnde ligi 90% naistest, kuid vaid 10% 
esineb endometrioos, siis on tõenäoliselt haiguse tekkesse kaasatud veel teisigi 
mehhanisme, näiteks häired immuunsüsteemi funktsioonis. Endometrioosi-
haigetel on kirjeldatud NK rakkude ja T lümfotsüütide tsütotoksilise aktiivsuse 
langust ning põletiku tsütokiinide ja autoantikehade tootmise tõusu, mis võivad 
soodustada endometrioosi kollete kasvu ning lisaks mõjutada ka viljakust. 
Endometrioos esineb reproduktiivses eas naistel ning enamasti taandub 
spontaanselt peale menopausi, seetõttu loetakse seda östrogeensõltuvaks haigu-
seks. Endomeetriumi kasvu reguleerivad östrogeen ja progesteroon, vastavalt 
kas stimuleerides või inhibeerides rakkude proliferatsiooni. Suguhormoonide 
retseptorid esinevad ka endometrioosikoes, mistõttu ka haiguskolded reageeri-
vad hormonaalsele miljööle. Erinevalt emakasisesest endomeetriumist, on 
endometrioosi kolletes ekspresseeritud kõik östrogeenide sünteesiks vajalikud 
ensüümid, kaasa arvatud aromataas ja 17β-hüdroksüsteroid dehüdrogenaas  
tüüp 1 (17β-HSD1), mistõttu on östrogeeni lokaalne tase haiguskolletes kõrgem 
kui normaalses endomeetriumis. 
On alust arvata, et endometrioosi tekkes on teatud roll ka geneetilistel 
faktoritel. Endometrioosihaige esimese astme sugulastel on haigestumisrisk ligi 
seitse korda kõrgem võrreldes üldpopulatsiooniga ning perekondlikel juhtudel 
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esineb sagedamini mõõdukat ja rasket endometrioosi kui sporaadilistel juhtudel, 
mis viitab võimalikule polügeensele pärandumise viisile. Endometrioosi riski 
mõjutavate geneetiliste faktorite kindlaks tegemine võimaldaks paremini mõista 
haiguse tekkepõhjuseid ja -mehhanisme ning aitaks seeläbi kaasa uute efektiiv-




Käesoleva uurimistöö eesmärgiks oli analüüsida seoseid erinevate kandidaat-
geenide ja endometrioosi haigestumise vahel. Lisaks soovisime uurida survi-
viinivastaste autoantikehade esinemist endometrioosi korral ning hinnata nende 
võimalikku rolli haiguse väheinvasiivses diagnostikas.  
Sellest tulenevalt olid töö alaeesmärgid järgnevad:  
 
1. Analüüsida endometrioosi haigestumise seost polümorfismidega sugu-
hormoonide sünteesis ja toimes osalevates geenides: östrogeeni retsepto-
rite geenid ESR1 ja ESR2, progesterooni retseptori geen PGR, 17β-HSD1 
geen HSD17B1 ning aromataasi geen CYP19A1. 
 
2. Uurida koe remodelleerimisega seotud maatriksi metalloproteinaaside 2 
ja 9 geenide MMP2 ja MMP9 polümorfismide mõju endometrioosi 
tekkele. 
 
3. Hinnata seoseid endometrioosi haigestumise ja angiogeneesis osalevate 
vaskulaarse endoteliaalse kasvufaktori geeni VEGFA ja angiotensiin-I 
konverteeriva ensüümi geeni ACE polümorfismide vahel. 
 
4. Analüüsida endometrioosi seost apoptoosi inhibiitori surviviini geeni 
BIRC5 polümorfismidega. 
 
5. Võrrelda endometrioosiga patsientidel ja kontrollindiviididel esinevat 
autoimmuunreaktsiooni surviviini vastu, määrates surviviinivastaste auto-
antikehade esinemist uuritavate seerumites. 
 
 
Materjal ja metoodika 
Uuringusse kaasati 150 endometrioosi diagnoosiga naist, 199 viljakat naist üld-
populatsioonist (kontrollgrupp A) ning 47 laparoskoopia läbinud patsienti, 
kellel endometrioosi ei esinenud (kontrollgrupp B). Iga uuringus osaleja kohta 
täideti küsimustik. Hospitaliseeritud patsientidelt võeti operatsiooni eelselt 15 
ml perifeerset verd, millest eraldati DNA ning seerum. Kontrollgrupp A naiste 
DNA-d ja kliinilised andmed saadi TÜ Eesti Geenivaramust. 
Geenivariatsioonide uuringus genotüpiseeriti kõigil naistel endometrioosi-
grupis ning kontrollgrupis A 22 polümorfismi 10 erinevas geenis: ESR1 PvuII 
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T/C, ESR1 (TA)n, ESR2 (CA)n, PGR +331G/A, PGR Alu Ins/Del, HSD17B1 
+1954A/G, CYP19A1 (TTTA)n, CYP19A1 TCT Ins/Del, CYP19A1 3’-UTR 
C/T, MMP2 -1575G/A, MMP2 -790T/G, MMP2 -735C/T, MMP9 -1562C/T, 
VEGFA -2578A/C, VEGFA -1154G/A, VEGFA -634G/C, VEGFA +936C/T, 
ACE -240A/T, ACE +2350A/G, BIRC5 -241C/T, BIRC5 -235G/A, BIRC5  
-31G/C. BIRC5 polümorfismid määrati ka kontrollgrupp B naistel. Genotüpi-
seerimisel kasutati järgnevaid meetodeid: PCR, restriktsioonanalüüs, alleel-
spetsiifiline PCR, sekveneerimine ja automatiseeritud fragmentanalüüs. Geno-
tüüpide ja haplotüüpide esinemissagedust võrreldi patsientide ja kontroll-
indiviidide vahel. Lisaks analüüsiti geenivariatsioonide seost nii endometrioosi 
raskusastmega, jagades patsiendid kaheks grupiks: I–II staadium ja III–IV 
staadium, kui ka patsientidel esineva viljatusega. 
Surviviinivastaste autoantikehade esinemine määrati ELISA meetodil 98 
endometrioosiga patsiendil ning kõigil naistel kontrollgrupis B. Hinnati nii anti-
kehade seost endometrioosiga üldiselt, kui ka haiguse erinevate staadiumide 
ning viljatuse esinemisega. 
 
 
Uurimistöö peamised tulemused ja järeldused 
Uurimistöö olulisemad tulemused on järgnevad: 
 
1. Variatsioonid suguhormoonide sünteesi ja toimega seotud geenides 
võivad mõjutada nii endometrioosi haigestumise riski kui ka viljatuse 
teket. Antud tööst ilmnes, et HSD17B1 geeni +1954A/G polümorfismi 
AA ja AG genotüübid on seotud kõrgema riskiga endometrioosi ja 
sellega kaasneva viljatuse tekkeks. Samas ESR2 geeni (CA)n mikro-
satelliidi lühemad alleelid on seotud endometrioosi riskiga, kuid ilma 
kaasneva viljatuseta. ESR1 geeni (TA)n lookuse pikemad alleelid näivad 
olevat seotud pigem viljatuse kui endometrioosiga. 
 
2. Variatsioonid MMP geenides on seotud endometrioosi riskiga. MMP2 
geeni promootorala -735C/T polümorfismi CC genotüüp suurendab 
haigestumise riski võrreldes TT ja CT genotüüpidega ning teatud 
promootorala haplotüüpidel näib olevat kaitsev efekt. MMP9 geeni 
promootori -1562C/T polümorfismi TT ja CT genotüübid on seotud 
kõrgema riskiga III-IV staadiumi endometrioosi tekkeks. 
 
3. Variatsioonid VEGFA geenis võivad mõjutada endometrioosi teket. 
VEGFA promootoralas oleva -2578A/C polümorfismi CC genotüüp on 
seotud madalama haigusriskiga. Antud töös uuritud ACE geeni variandid 
ei mõjuta endometrioosi haigestumist. 
 





5. Humoraalne autoimmuune reaktsioon surviviini vastu on sarnane endo-
metrioosihaigetel ja tervetel naistel, mistõttu surviviinivastaste autoanti-
kehade määramist seerumis ei saa kasutada endometrioosi diagnostikas. 
Autoantikehade tase näib olevat seotud pigem BIRC5 -235G/A polümor-
fismi ning suitsetamisega. 
 
Kokkuvõttes näitavad käesoleva uuringu tulemused, et teatud variatsioonid nii 
suguhormoonide sünteesi ja toime kui koe remodelleerimise ja angiogeneesiga 
seotud geenides võivad mõjutada endometrioosi teket. Lisaks on antud töö 
esimene, mis kirjeldab ESR2 geeni (CA)n mikrosatelliidi seost haigestumis-
riskiga. Tulemuste analüüsimine viljatutel ja viljakatel patsientidel eraldi näitas, 
et teatud geenivariatsioonide puhul ilmneb seos endometrioosiga sõltuvalt 
sellest, kas haigusega kaasneb viljatus või mitte, viidates võimalusele, et 
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